Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America by Alonso Padilla, Julio et al.
For Peer Review Only
Strategies to enhance access to diagnosis and treatment for 
Chagas disease patients in Latin America.
Journal: Expert Review of Anti-infective Therapy
Manuscript ID ERI-2018-ST-0154.R1
Manuscript Type: Perspectives
Keywords: Chagas disease, comprehensive care, clinical trials, diagnosis, drug treatment, patients associations, pharmacovigilance, vector control
 
URL: https://mc.manuscriptcentral.com/eri   Email: IERZ-peerreview@journals.tandf.co.uk
Expert Review of Anti-infective Therapy
For Peer Review Only
1
Title: Strategies to enhance access to diagnosis and treatment for Chagas disease patients 
in Latin America.
Structured abstract (maximum 200 words): Chagas disease, caused by infection with 
the parasite Trypanosoma cruzi, represents a huge public health problem in the Americas, 
where millions of people are affected. Despite the availability of two drugs against the 
infection (benznidazole and nifurtimox), multiple factors impede their effective usage: 1) 
gaps in patient and healthcare provider awareness; 2) lack of access to diagnosis; 3) drug 
toxicity and absence of treatment algorithms to address their adverse effects; 4) failures 
in drug supply and distribution; and 5) inconsistent drug efficacy against the symptomatic 
chronic stage. Here we review new approaches and technologies to enhance diagnosis 
and treatment algorithms as a means to reduce the disease burden. We also provide an 
updated picture of recently published and ongoing anti-T. cruzi drug clinical trials. 
Although there has been progress improving the research and development (R&D) 
landscape for this traditionally forgotten disease, it is unclear whether any new licensed 
treatments will emerge soon. Therefore, in parallel with R&D approaches we summarize 
the needs to continue awareness and advocacy efforts by patient associations, local and 
national governments and international agencies, and why health system strengthening is 
essential to ensure vector control commitments, as well as patient access to diagnosis and 
treatment.
Keywords:  Chagas disease, comprehensive care, clinical trials, diagnosis, drug 
treatment, patients associations, pharmacovigilance, vector control.
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1. Introduction.
Chagas disease, or American trypansosomiasis, is caused by the protozoan 
parasite Trypanosoma cruzi (T. cruzi) and remains one of the most deadly and intractable 
neglected tropical diseases (NTDs) in the Western Hemisphere [1].  Updated information 
from the Global Burden of Disease Study (GBD) 2016 indicates that 7,100 people die 
from Chagas disease annually, roughly the same number of Chagas disease-related deaths 
that occurred a decade previously [2]. However, these numbers may represent highly 
conservative estimates with further findings that as many as 200,000 people living with 
T. cruzi infection may die over the next five years [3]. The GBD 2016 also finds that 7.2 
million now live with Chagas disease, while 180,000 new T. cruzi infections occur 
annually [4].
Beyond its horrific disease burden and contribution to infectious disease mortality, 
there is a profoundly disturbing social impact dimension to Chagas disease related to its 
importance as a health disparity. Today, tens of thousands of people face a death sentence 
from their T. cruzi infection due to Chagasic cardiomyopathy, which could be prevented 
by timely access to diagnosis and anti-parasitic treatment with one of two 
nitroheterocyclic drugs – benznidazole (BNZ) and nifurtimox (NFX). Fueling a growing 
outrage from the global health community is the finding that approximately 90% of 
people infected with T. cruzi infection now live in Latin America’s three wealthiest 
economies: Argentina, Brazil, and Mexico. In the United States of America (USA), the 
richest country of the continent and main destiny of those looking for a better future, there 
are at least 200,000 immigrants from Latin America living with Chagas disease with 
limited or no access to treatment [5,6]. Furthermore, in Europe there are around 120,000 
immigrants from Latin America living with Chagas diseases with a disparity of situations 
regarding access to care and treatment [7,8].
The overwhelming majority of Chagas disease sufferers are unable to gain access 
to diagnosis and treatment, not only because they are poor, but also because governmental 
leaders are either uninformed or uninterested. For example, it is noteworthy that the 
registration of BNZ for the treatment of pediatric Chagas disease in the USA has not been 
approved until very recently [9]. Documenting such assertions is not easy and seeking 
solutions to diagnosis and treatment access are not straightforward endeavors. In Mexico, 
for example, there are almost one million people living with Chagas disease, although 
even that number may represent a profound underestimate [10]. Yet, only 3,013 T. cruzi 
infection cases were registered nationally between the years 2007 and 2011, less than 1% 
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of the actual number of people affected with the disease [11]. A similar situation has been 
documented for the USA [12] and also likely holds true across the Americas. We are 
facing a situation where less than 1% of Chagas disease patients have access to timely 
and appropriate diagnosis and treatment [13,14].
Limiting access to essential medicines also has important implications for new 
research and development (R&D) related to therapeutic interventions. An exciting 
development on this front is a new orally bioavailable nitroheteorcyclic drug, 
fexinidazole, which is also effective against human African trypanosomiasis [15]. 
Additional drugs are also under development, as well as there are Chagas disease vaccine 
(immunotherapeutic) candidates at pre-clinical stage [16]. In this respect, the Texas 
Children’s Hospital Center for Vaccine Development, a Product Development 
Partnership, is exploring an approach that links therapeutic vaccination to 
pharmacotherapy [17]. However, any R&D successes must still face a formidable 
gauntlet of truncated and mostly failed global access mechanisms. Similar forces are a 
barrier for access to new and innovative diagnostics [18].
Here we report on some of the major hurdles that currently block access to the 
diagnosis and treatment of Chagas disease. The problems include both scientific and 
socioeconomic obstacles. This paper aims to elucidate the challenges they pose and offer 
solutions.
2. The need of more practical and useful diagnostics.
The poor access rate to Chagas disease therapeutic treatments has its roots in the 
clinical nature of the disease itself and its silent progression from the mostly 
asymptomatic acute stage into the symptomatic chronic one [1]. Unfortunately, 
biomarkers of disease progression and standardized tools to  determine early response-to-
treatment are yet unavailable, which greatly complicates the prognosis and follow-up of 
patients [19].  
Treatment administration, as in any other disease, needs to be preceded by an 
adequate diagnosis. In the case of Chagas disease, when a clinical diagnosis is achieved, 
tissue disruptions might already be too advanced for a chemotherapeutic intervention. 
Therefore, parasite detection must be sought before the onset of overt symptomatology. 
In the acute infection stage, for instance upon congenital transmission of the parasite, 
parasitemia can be detected by direct microscopic observation [1]. However, this stage is 
short lasting and generally goes unnoticed as there are often no symptoms at all. 
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Approximately 30% of these infected individuals will progress to evidence of either 
Chagasic cardiac or gastrointestinal disease. Those without clinical evidence of disease 
are said to be at the indeterminate stage, whereas those with cardiac or gastrointestinal 
involvement are at the determinate stage. The development of life-threatening heart 
and/or digestive tract disruptions, which can be massive and are called mega-syndromes, 
occurs in the long lasting chronic stage that follows [1]. 
In both indeterminate and determinate Chagasic patients parasitemia is typically 
low and intermittent and the diagnosis of the infection is made by means of indirect 
serological tests, like enzyme-linked immunosorbent assays (ELISAs). This is possible 
because high levels of parasite-specific immunoglobulins are produced upon T. cruzi 
infection (Figure 1). Anti-T. cruzi type G immunoglobulins (IgGs) levels remain above 
detection thresholds for many years, which is advantageous for the serological diagnosis 
of the infection (Figure 1). However, it turns out to be an inconvenience for a serology-
based assessment of drug responses as it can take several years for them to revert after 
the administration of treatment [20]. 
Some studies indicate that treatment interventions while patients are in the 
indeterminate or early determinate stages are critically important in order to prevent 
advanced disease progression. In contrast, from the multi-centered BENEFIT trial to 
evaluate benznidazole efficacy it was found that patients with significant cardiac 
involvement progressed to advanced disease or even died despite receiving specific 
antiparasitic chemotherapy [3,21]. Currently a Kushnir grading system is in place to 
differentiate people with early-stage (grades I-II) versus late stage (Kushnir III-IV) 
determinant cardiac disease [1]. Treatment  of patients with Kushnir grades III-IV was 
not encouraged previously [1], a finding that appears to hold up in light of the recent 
BENEFIT findings.
These findings highlight the importance of identifying both indeterminate patients 
with Chagas disease and possibly those with Kushnir grades I-II since they might be 
successfully treated with antiparasitic therapy if they were captured during  population-
wide screening campaigns [3]. In this way, it would be possible to identify and treat 
chronically infected people before they develop the symptomatology. Women at child-
bearing age and newborns should receive special attention because the treatment of 
mothers-to-be has been shown to largely reduce the transmission rate [22–25], and the 
efficacy and tolerability of current drugs by infected newborns is ~100% [1]. Moreover, 
health economics studies evaluating Chagas disease surveillance in endemic and non-
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endemic settings indicate that widespread screening would be highly cost-effective [26–
29]. In the two disease scenarios studied, congenital (acute infection transmitted by 
chronically infected mothers) and indeterminate (chronic asymptomatic stage), mass 
screening would save health costs even at T. cruzi prevalence rates as low as 0.9% or 
0.05% respectively (estimated in the non-endemic setting) [26,28].
Due to the very limited resources available for Chagas disease management, and 
echoing the answers provided by Latin American experts enquired by Picado et al. [18], 
efforts should focus on making widely available point-of-care (PoC) tests to diagnose 
congenital transmission and indeterminate chronic patients [18]. However, if we want to 
enable generalized Chagas disease diagnosis, there is an urgent need of more practical 
diagnostic reagents and kits. Availability of easy-to-use tools for the early assessment of 
treatment response would also be highly valuable to promote and support the 
administration of drugs against the infection. In this regards, there are some biomarkers 
under research [19], but the evaluation of anti-T. cruzi drug responses yet relies on the 
molecular amplification of the parasite DNA from periphery blood obtained at distinct 
times post-treatment. Unfortunately, its associated high costs and technical requirements 
restrict its use to the context of well-funded clinical trials [30].
2.1. Current Chagas disease diagnostics are impractical in many regions.
Regarding acute stage diagnostics, classical parasitological methods 
(micromethod, hemoculture and xenodiagnoses) are microscopy-based and rely on 
finding motile trypomastigotes in blood, thus they provide both low sensitivity and 
specificity. Due to their poor performance, current algorithm to diagnose congenital 
transmission involves two micromethods (at birth and at 1-2 months of age), and a further 
confirmatory serological test once mother-derived IgGs have waned at infant´s 8-12 
months of age [31]. This has two major drawbacks: a very high loss-to-treatment risk 
during pediatric follow up, and the reduction of drug efficacies the longer the treatment 
is delayed [31]. Molecular amplification of T. cruzi DNA, either by conventional 
polymerase chain reaction (PCR) or by quantitative PCR (qPCR), has been shown to be 
more sensitive and specific than classical parasitological techniques [20]. Several 
laboratories have worked on the standardization of the techniques so that their outcomes 
can be comparable and implemented in clinic-based laboratories [20]. But molecular 
biology laboratories are expensive to mount and maintain, plus they require highly trained 
personnel to run them. Therefore, despite its very good performance, molecular detection 
Page 5 of 99
URL: https://mc.manuscriptcentral.com/eri   Email: IERZ-peerreview@journals.tandf.co.uk





























































For Peer Review Only
6
is not generally used beyond regional or national reference laboratories in endemic 
regions.
In relation to the current chronic stage diagnostics, conventional serological tests 
(like ELISAs, indirect immune-fluorescence or indirect hemagglutination assays) use 
serum or plasma samples that entail venous extraction and blood segregation by 
centrifugation, and they require a cold chain to preserve the test reagents and the samples. 
Moreover, due to the parasite´s antigenic diversity, the advice from the World Health 
Organization (WHO) is to run two tests based on distinct antigenic sets and if their 
outcomes are not concurrent, to employ a third technique [14]. This algorithm is costly, 
and it requires equipment and resources that are usually not available in many laboratories 
of endemic regions. Furthermore, the turnaround of results to the patient can take several 
weeks, which involves a high risk of losing contact with the patient for treatment.
2.2. What solutions could be implemented?
Fortunately, recent technological advancements are procuring solutions to 
overcome the limitations mentioned above. We will outline them separately considering 
first those for the diagnosis of acute stage and then those for the diagnosis of chronic 
Chagas disease.
In recent years, isothermal amplification methods that do not require expensive 
equipment (such as thermocyclers or gel visualization systems) and are easier to perform 
than PCR assays have been developed for the molecular detection of several NTDs [20]. 
At present, a prototype of Loop isothermal AMPlification for T. cruzi-DNA (LAMP, 
Eiken Co., Japan) has been tested with clinical samples and shown to have a comparable 
performance to qPCR with blood-EDTA samples [32]. Another LAMP test developed in 
house by Rivero et al. [33] has also been shown to provide a comparable performance to 
current congenital transmission algorithm. LAMP is based on a microbiological DNA 
polymerase that works at a constant temperature of 65 ºC for 45 minutes with a set of 4 
to 6 complex primer sequences to provide a highly sensitive and specific amplification 
[34]. LAMP readout is qualitative and the results can be naked eye visualized in a short 
time given a probe (e.g. calcein) is added to the reaction mix. If a digital fluorimeter is 
used (e.g. Genie III) the reading can even be semi-quantitative [32]. Notably, in EIKEN´s 
T. cruzi-LAMP prototype, reagents are provided dried out in the lids of the reaction tubes 
which allow a ready-to-use format and a much desirable room temperature storage [32]. 
More recently, a Recombinase Polymerase Assay (RPA), which even requires a lower 
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amplification temperature and shorter amplification time (40 ºC for 30 min) than LAMP, 
has been tested with samples from naturally T. cruzi-infected dogs [35]. This RPA has 
been coupled to a lateral flow strip for results reading and it was shown to provide 
excellent agreement with qPCR results [35]. There are RPAs for the detection of other 
NTDs [36,37], so it could also be very useful for Chagas disease molecular diagnosis.
For the serological detection of T. cruzi-specific IgGs, rapid diagnostic tests 
(RDTs) have been commercially developed during the last two decades [38,39]. RDTs 
have clear advantages over conventional serology, as they can be stored at room 
temperature, use a very small volume (5-25 µl) of finger pricked whole blood, have an 
easy-to-run and read cassette format, and provide a fast turnaround of results (less than 
45 minutes) [39]. Several studies now support their implementation as they have been 
extensively validated against conventional tests [40–42]. For instance, a RDT is currently 
used for primary screening of chronic Chagas disease in Bolivia [38]. Nonetheless, 
following the WHO guidelines of two-tests concordance, confirmation of that RDT 
primary result must yet be made with a conventional serological test [14].  Such 
recommendations reduce the advantages of RDTs.
With the aim to fully exploit RDTs advantages and to determine whether they can 
substitute conventional tests, combinatory use of two RDTs has been proposed [40]. So 
far, in a proof-of-concept study performed in the city of Sucre (Bolivia), perfect 
agreement between the two RDTs used was observed, and their sensitivity and specificity 
in comparison with three conventional tests was 100% and 99.3%, respectively [40]. 
However, despite a promising performance in Bolivia [40,42], RDTs have not worked so 
well when they have been used in other geographical regions [43]. This might be related 
to the high prevalence of the disease in Bolivia, which may allow an easier detection, or 
to the fact that the parasite strains used to produce the RDTs antigens are those circulating 
in Bolivia. In any case, until more results from different epidemiological areas are 
available, preliminary geographical testing of the RDTs performance has been proposed 
before using them in a particular region [43]. In view of the advantages they bring versus 
conventional tests, RDTs implementation for Chagas disease surveillance should be 
evaluated at larger scales. 
3. Treatment of Chagas disease, and issues related to it.
3.1. Drug regimens.
Evidence about the benefits of Chagas disease treatment, together with a growing 
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understanding of the pathogenesis of the disease, led to the paradigm that all T. cruzi-
seropositive patients should receive treatment with anti-T. cruzi drugs [44]. The recently 
published results of the SaMi-Trop cohort study further reaffirm this statement as they 
demonstrate a beneficial effect of BNZ in reducing the cardiac clinical progression of 
chronic Chagas disease patients [45]. Therefore, anti-trypanosomatid should be provided 
to all T. cruzi-infected people who do not present with  advanced cardiac complications 
(Kushnir grades III-IV), as by then clinical manifestations might not be improved [46]. 
Nonetheless, access to treatment confronts important limitations. BNZ and NFX, the only 
drugs available for T. cruzi infection, exhibit reduced efficacy during the chronic stage of 
the disease, and require a long period of administration which causes frequent unwanted 
drug-related adverse reactions (ADRs) [47–49]. Furthermore, variable drug susceptibility 
has been already described among distinct T. cruzi strains [50]. In this context, there is an 
urgent need for more efficacious and safer drugs or drugs´ regimens, in particular for the 
treatment of the chronic stage of the infection.
One alternative is the reduction of the BNZ dose and/or schedule in order to 
improve safety and adherence to treatment; an approach that is supported by clinical and 
experimental data. In a pilot study Álvarez et al. [51] assessed a new scheme of BNZ 
administration in a small cohort of chronic Chagas disease patients treated with 
intermittent doses of BNZ at 5 mg/kg/day every 5 days for a total of 60 days. The study 
showed a satisfactory safety profile, with low rates of treatment suspension and treatment 
failure [51]. Furthermore, an experimental study using a mouse model of chronic T. cruzi 
infection demonstrated the effectiveness of an intermittent scheme of BNZ administered 
every 5 days for 40 days [52]. These findings support the intermittent administration of 
BNZ as a new dosage schedule, but further research to confirm its efficacy by long-term 
assessment of larger cohorts is needed. Another therapeutic option under investigation is 
the co-administration of an immunotherapeutic (vaccine) treatment and BNZ. In this 
regards, enhancement of a T. cruzi-specific immune response has been shown to 
contribute to support the efficacy of reduced BNZ dosages in a mouse model of acute T. 
cruzi infection [17].
3.2. Drug availability.
Drug access is still a huge problem in some endemic areas [13]. BNZ, generally 
the first line therapy for Chagas disease, is part of the WHO List of Essential Medicines 
[53]. It was produced during more than 40 years by Roche (Basilea, Switzerland), which 
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transferred its production rights to Laboratório Farmacêutico de Pernambuco (LAFEPE), 
a Brazilian public enterprise, at the end of the twentieth century. Sadly, BNZ production 
and distribution by LAFEPE failed to meet expectations in terms of meeting supply and 
demand requirements and in 2011 an important shortage of the drug occurred. It lasted 
1.5 years and left thousands of patients without treatment worldwide [13,53]. This fact 
led to the development of a Private-Public Partnership in Argentina involving Maprimed 
(for the synthesis of the drug) and ELEA (for its development and production), to promote 
equitable availability of BNZ [55]. Since 2012, this Argentinian Partnership has worked 
to guarantee the availability of the drug, distributing BNZ to the countries in the region 
[55]. NFX, which is mostly used as the second line treatment option, is produced and 
donated by the pharmaceutical company Bayer, and distributed through the Pan-
American Health Organization (PAHO) Strategic Fund [56]. Recently, a NFX produced 
by Gador has also been registered in Argentina. Definitely, a regular, safe and accessible 
production of these two antiparasitic drugs is necessary to guarantee the treatment to 
diagnosed patients, and the access to drugs has to be ensured in adequate quantity, quality, 
location and timing.
3.3. Pharmacovigilance.
A major limitation of current Chagas disease treatments is the onset of Adverse 
Drug Reactions (ADRs), which may lead to poor medication adherence, and cause 
thereby therapeutic failure or ineffective treatment [46-48]. ADRs are defined as "an 
appreciably harmful or unpleasant reaction, resulting from an intervention related to the 
use of a medicinal product, which predicts hazard from future administration and warrants 
prevention or specific treatment, or alteration of the dosage regimen, or withdrawal of the 
product” [57]. The most commonly observed ADRs related to BNZ are headache, 
dermatological manifestations and gastrointestinal symptoms [47,48]. Concerning NFX, 
digestive symptoms are the most frequent [46]. Nevertheless, with an adequate clinical 
management most of the patients are able to finish treatment in the advent of ADRs [47]. 
Close medical follow-up, adequate monitoring of ADRs and implementation of robust 
pharmacovigilance systems are essential factors to avoid patient abandonment and 
achieve therapeutic success.
Although pharmacovigilance is crucial, it is still a neglected area. Latin-American 
countries are making important efforts to report ADRs, but these activities are recent and 
need reinforcement [58,59]. Results of an unpublished study conducted by Cortes-Serra 
Page 9 of 99
URL: https://mc.manuscriptcentral.com/eri   Email: IERZ-peerreview@journals.tandf.co.uk





























































For Peer Review Only
10
et al. in Bolivia during 2016 indicate that 35.4% of the total patients treated for Chagas 
disease in fourteen healthcare centers of the department of Cochabamba suffered ADRs 
related to it. From all ADRs classified as moderate or severe (25% of the total ADRs 
registered), only about half of them (51.43%) were reported to the Bolivian 
Pharmacovigilance system [60]. This data illustrates the urgency of implementing 
policies to promote training in pharmacovigilance to all healthcare professionals, as well 
as strictly recommend the follow-up on drug monitoring and ADR reporting. Altogether, 
these features are fundamental to achieve strong and consolidated ADR reporting 
systems, which will improve patient safety, drug efficacy and adherence to treatment. 
4. Patients´ comprehensive care: reference and counter-reference circuits.
With less than 1% people treated [13,14], and an economic burden of $7.19 billion 
per year and $188.80 billion per lifetime [61], Chagas disease remains neglected despite 
the efforts performed by several institutions focused on development and research [13]. 
Migratory flows have changed the epidemiology of the disease that is now emerging in 
some non-endemic countries [7]. During the last decades, collaboration and knowledge 
transfer between institutions from endemic (CEADES, Bolivia) and non-endemic 
countries (ISGlobal, Spain) has been strategic to build attention models for the Chagas 
disease patient. Such models could be scaled-up by national health systems in endemic 
and non-endemic countries in order to expand Chagas disease healthcare to people living 
in areas with limited access to health (e.g. rural areas in endemic countries) or to 
vulnerable populations (e.g. migrants in endemic and non-endemic countries).
4.1. The Platform for integral care of Chagas disease patients.
The work made by this Platform in recent years have produced a quantitative and 
qualitative improvement in the healthcare provided to Chagas disease patients in Bolivia, 
but this improvement certainly needs to be strengthened. The experience gained with the 
Platform in the country has shown that the implementation of specialized centers to 
manage people at risk of having Chagas disease is highly effective, both based on the 
percentage (and number) of people diagnosed with the infection, and amongst them, those 
who received and completed treatment [62]. This vertical strategy has been essential to 
design the attention model for patients with Chagas, making the medical assistance to 
these people look like a normalized and necessary action [62]. Nevertheless, the 
sustainability of such model ultimately depends on continuously securing external funds, 
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which greatly complicates its expansion to larger geographical levels, like national 
coverage by the national health system (Figure 2).
4.2. Vertical-to-horizontal healthcare model transition.
In order to have a higher impact in terms of diagnosis and treatment coverage, as 
well as to ensure the sustainability for the model of care of Chagas disease patients already 
installed, it is mandatory to search for a comprehensive horizontal strategy together with 
local higher level entities of the public health system. In fact, based on WHO 
recommendations, the strategy to include the Chagas disease attention roadmap as part of 
the regular activities of all healthcare levels seems to be the most appropriate approach 
[63].
Simplifying the vertical Chagas disease model of healthcare to more realistic 
protocols established together with the national health institutions has allowed the 
improvement of healthcare access for people at risk of having the disease living in remote 
areas of an endemic country [62]. Researchers at ISGlobal (authors of this review) have 
yet unpublished data which demonstrate that the health coverage, in terms of patients 
diagnosed and treated in the selected area in which the project has expanded its activity, 
was five times higher in the three years following the horizontal comprehensive care 
model than the number of people covered in the five previous years with the vertical 
strategy (Pinazo et al, unpublished).
So far, the outcome of the vertical-to-horizontal healthcare model transition 
highlight that it could be worthy to replicate and/or adapt it to other regions or countries. 
The first step would be to coordinate with local health authorities at different levels in 
order to design an appropriate strategy. For the implementation of a healthcare model, the 
identification of interested health workers is a key issue. Even if it is simplified, a strategy 
to offer a comprehensive care for people at risk of suffering from Chagas disease should 
include: (a) specific training of health workers on the disease management; and (b) a 
strategy to increase the demand of the civil society, based on promotional and educational 
community activities. In this regard, the establishment of referral and counter-referral 
circuits tailored to each epidemiological and logistic situation is highly relevant, even in 
nearby areas.
4.3. Requirements for the expansion of the Chagas disease healthcare model.
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Referral and counter-referral circuits, in terms of patients and samples for 
diagnosis or any other test, should include different healthcare levels to cover different 
levels of complexity in terms of care. The specialized centers in which the model of care 
has been rehearsed in Bolivia are key towards organizing these circuits, as well as to act 
as reference centers for complicated cases and to accompany the doubts and the 
continuing education of health professionals from primary care centers. This is 
particularly important in health systems where there is often a fast renewal of healthcare 
personnel. Another crucial point to make sustainable a comprehensive horizontal strategy 
against Chagas disease is to promote an inter-sectorial collaboration with vector control 
authorities (promoters of house refurbishment, disinfestation programs,...) and the 
educational system itself. Vector control interventions are fundamental to halt vector-
dependent transmission and enable an enhanced drug control of the cases. Whereas 
educational activities to widen the population knowledge and perception of the disease, 
its impact, and treatment possibilities are crucial, because producing changes in beliefs, 
attitudes, and behaviors on both medical staff and patients still stands as one of the major 
challenges that must be faced when dealing with Chagas disease. All these measures have 
a role to play in order to consolidate the successful management of the disease.
On the other hand, lessons learned from the primary healthcare network have 
shown that it is mandatory to ensure the supervision of the circuits and surveillance the 
quality of the process, tasks that should be carried out by the national health system 
responsible personnel in duty. Political engagement at this point is mandatory to 
contribute to a better control of the disease as a Public Health problem. In this context, it 
is important to respect the capability of local health institutions, agreeing with them 
timelines and a progressive increase of the number of people diagnosed and treated, in 
order to answer adequately to people’s demands. It must be noted that external factors 
like the poor availability of drugs for Chagas disease treatment have a sourly negative 
impact on any planning.
5. Patients treatment in relationship with vector control.
Access to diagnosis and treatment of Chagas disease in areas with active vector 
transmission requires a multidisciplinary approach. It involves the participation of players 
from several areas of expertise and different government sectors, from vector control 
authorities to health service providers, including primary healthcare [64].
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Following the advice from the PAHO, intergovernmental regional initiatives were 
created at the end of the twentieth century and beginning of the twenty first century to 
establish supranational levels of action to bolster and monitor the implementation of 
activities to prevent, control, diagnose and treat Chagas disease in Latin America. These 
initiatives were started by Southern Cone countries in 1991, and then followed by Andean 
countries and Central American countries in 1997 and Amazonian countries in 2004 
[65,66]. Despite these efforts, it is evident that in the region there was, and still is, a breach 
between the programs for vector control and the areas that are responsible for providing 
universal health care (including diagnosis and etiological treatment) [67].
It is important to consider that although policies related to the primary prevention 
of Chagas disease are defined at the national level, primary healthcare attention for the 
patient is the responsibility of the provincial/departmental or municipal/local entities [68]. 
Often times, these final effectors of national policies have little or no 
relation/communication with the national entity and are sometimes even unaware of the 
policies themselves. For example, suggestion of treatment of the infection by T. cruzi for 
postpartum women and their newborns, and the mandatory treatment for women of 
childbearing age and children under the age of one with Chagas disease that are in the 
national or supranational norms [31], make no specific mention of which protocols need 
to be applied with respect to vector surveillance in the houses of those patients living  in 
endemic areas with active vector transmission. However, recent public health 
interventions have shown that activities related to access to diagnosis or treatment of the 
disease are usually implemented and promoted by those responsible for vector control 
programs [69]. Thus, without consideration of the need of appropriate structures and 
circuits (i.e. access to an adequate laboratory for diagnosis or presence of anti-
trypanosomal drugs), which are not usually present in rural areas, one of the main actions 
needed is to establish and/or strengthen the link between vector control programs and the 
health system providers [69]. Thereafter, following a stepwise approach, another action 
to accomplish would be to provide technical recommendations to establish criteria for 
categorizing the risk of vector transmission status in an endemic area. With that 
information available, it could be possible to explicitly detail under which conditions 
Chagas disease diagnosis and treatment has to be made mandatory in the area for the 
entire population, or segments of it (i.e. women at childbearing age, newborns). Finally, 
a most desired third action would definitely be to integrate the procedures for disease 
diagnosis and treatment within the health system as a transversal program.
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Nowadays there are already a few experiences that have been able to coordinate 
vector control actions together with diagnosis and treatment in a successful manner [70, 
71]. These could serve as proof-of-concept strategies for integral interventions to build 
on, improve and replicate. As an example, the experience of Fundación Mundo Sano, 
with direct and uninterrupted action in the field since 2002, is worth mentioning. Its 
integral program includes vector control and sanitary improvement of rural houses in the 
Department of General Taboada (Santiago del Estero, Argentina). In 2015, after 13 years 
of vector surveillance and control, Mundo Sano was able to install two doctors’ offices 
dedicated to the diagnosis and treatment of Chagas disease together with local 
institutions, one in Añatuya City and another one in Colonia Dora. Since then, they have 
been struggling with the problems of having a mono-disease health service in a 
community that did not demand treatment. Despite the difficulties, after almost three 
years of implementation, the amount of people diagnosed and treated begun to increase. 
The work from these two Chagas disease specific offices was integrated to the local 
hospital of Añatuya in 2018, thus reaching a higher amount of T. cruzi-infected 
individuals derived from obstetrics, gynecology and cardiology services in addition to 
those attending the offices from spontan ous demand. In the same line, the Platform for 
the Integral Care of Chagas disease Patients was settled in Bolivia in 2009. Initially in the 
province of Cochabamba in the center of the country, the Platform now works also in 
municipalities of the provinces of Chuquisaca and Tarija [62]. Each experience, proposal 
or pilot study must be evaluated objectively in order to improve and multiply its impact, 
avoiding a future with a new inequality: one were those affected by the disease will have 
access to health depending on whether they live in an endemic or non-endemic area.
6. The role of patients’ associations.
Similarly to what happens with other NTDs programs to promote scaling up of 
healthcare interventions, strategies towards the control of Chagas disease often confront 
with structural weaknesses of the health systems in which they aim to be integrated [72–
74]. Therefore, more effective strategies to strengthen those health systems are required 
to ensure a sustainable integration of the required health innovations within them. 
Importantly, these strategies need to incorporate the patients´ perspective in order to 
overcome key access barriers [13,14,75]. Barriers that nowadays still hinder the access to 
diagnosis and treatment, barriers impeding a better health care.
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In recent years, several associations of Chagas disease patients have emerged and 
joined in a Federation of Associations whose purposes are: (i) to increase the visibility of 
the disease at all levels as well as of its overwhelming impact in the patients´ health status; 
and (ii) to promote a more active role of the people affected by the disease in the decision-
making processes. But these associations face many difficulties (dispersion of objectives, 
multiplicity of voices with different requirements, little real mobilization in many 
countries, and lack of resources) to achieve their objective of having an effective role in 
the health policies makings of their countries.
The WHO global strategy on integral health services centered on people could be 
a way through which these associations can play an important practical role [76]. In fact 
one of the goals of such program is to empower individuals, families and communities by 
including in it some well-known activities led by patients such as community education, 
groups of patients for mutual support, expert patients to engage and help others, etc. [76]. 
In addition, this WHO program goes beyond a single disease and has the virtue of 
encompassing other actors with decisive roles in health systems performance, like 
governmental policy-makers, municipalities, donors, and providers. 
Overall, the strategy is thus envisaged to allow the community and patients to 
actively participate in the decision-making process, together with other involved actors, 
in issues regarding their health. By doing so, they also play a role on the way the health 
system is organized, for instance ensuring that community and primary healthcare are 
prioritized. Therefore, patients associations should look after the implementation and 
compliance with this WHO strategy as it underlies the activities they are already taking 
on.
7. The R&D Agenda: clinical trials for new drugs or new strategies of treatment 
with current drugs.
7.1. Results from recently completed trials.
Upon the questioned efficacy of currently available therapies (BNZ and NFX) 
against the chronic symptomatic stage of the disease, clinical testing of new drugs and/or 
of new regimens of BNZ and NFX is being pursued. Nonetheless, some major obstacles 
are in the way to getting more adequate treatments, including the poor understanding of 
the infection pathophysiology leading to the disease clinical progression, and the lack of 
biomarkers to determine prognosis and cure (see review by Pinazo et al., [19]). 
Particularly the latter hinders the follow-up of treated patients both in the daily clinic and 
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in clinical trials. At present, an absence of molecular amplification of T. cruzi DNA from 
periphery blood is used as surrogate of “treatment success”. But this approach is far from 
optimal, especially at the chronic stage of the disease when the parasitemia is low and 
intermittent. A negative result obtained at a determined time point does not exclude the 
possibility that a positive one will be obtained in the next visit. A false-negative PCR, 
i.e., a negative PCR result (“treatment success” event) in the patient follow up is then less 
informative than a positive determination, as this one will indeed define a case of 
treatment failure.   
Despite this limitation, several clinical trials have been completed in the last years, 
and there are several more currently ongoing. This advance represents a major shift in the 
research landscape of this historically forgotten NTD. The vast majority of the performed 
trials have been Phase 2 randomized, multi-centric, double-blinded, efficacy and safety 
studies to evaluate oral dosage schemes for the treatment of adult patients at indeterminate 
(asymptomatic) chronic stage (see Table 1). Amongst them, CHAGASAZOL [77], STOP 
CHAGAS [78] and E1224 [30] have evaluated for the first time two triazole anti-fungal 
drugs (posaconazole (POS), and the ravuconazole precursor E1224) for their anti-T. cruzi 
properties. In addition, the BENEFIT trial that evaluated the use of BNZ for chronic stage 
treatment must also be highlighted as it has been the largest Phase 3 Chagas disease trial 
performed so far [46].
CHAGASAZOL and E1224 trials entailed a direct comparison of POS and E1224 
monotherapy at a high and a low dose to a BNZ standard dosage group (5 mg/kg/day 
orally divided in two daily doses for 60 days) [30,77]. In addition to monotherapy 
branches, STOP CHAGAS trial also included a study group that received POS and BNZ 
as combined therapy [78]. In the latter, treatment success was defined as a negative PCR 
value at the day 180 follow-up visit [78], whereas parasitological cure in CHAGASAZOL 
was determined by a negative PCR result at 12 months follow-up [77]. The most stringent 
success criteria was that of E1224 trial, which involved serial negative PCR results (3 
negative PCR results from 3 samples collected over 7 days) at 65 days after end of 
treatment and a further negative PCR outcome at 12 months follow-up [30]. 
Although both POS and E1224 drugs showed good safety and efficacy profiles at 
end of treatment in the three studies, the suppressive effect on parasite clearance after 12 
months was much reduced in comparison to BNZ, which showed early and sustained 
efficacy until 12 months of follow-up (Table 1). Thus, neither POS nor E1224 were as 
good as BNZ and could not substitute it as monotherapies.
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In the BENEFIT trial, the treatment response was evaluated in a sub-group of 
1,896 subjects who had PCR results at baseline (60.5% of them were positive) by PCR 
conversion at the end of treatment, and at two and five years post-treatment [46]. Being 
a large multi-national study, the PCR conversion rates varied geographically with Bolivia 
and Argentina showing the best results, though it must be noticed that such conversion 
did not correlate with clinical outcome [46]. BENEFIT was devised to study whether 
BNZ administration to patients at the chronic stage of the disease would widely have a 
clinical benefit for them [21,46]. Sadly, its conclusions, far from reassuring the role of 
BNZ turned out to be a setback, as they suggested not-to treat patients with advanced 
cardiac disease [46]. As it has been criticized elsewhere, this devastating conclusion 
drains from the fact that many subjects with advanced cardiac involvement were enrolled 
in the study [3,21]. Despite its negative outcome due to a rather questionable study 
protocol design [21], the BENEFIT trial involved ample cooperation between multiple 
study sites opening the door to the performance of multi-national Phase 3 Chagas disease 
trials in South America [46]. 
7.2. Ongoing clinical trials of anti-T. cruzi drugs.
There are now some active and/or ongoing clinical trials. Some test alternative 
BNZ dosing regimens to reduce exposure, improve tolerability and maintain efficacy as 
described elsewhere [51], based also on the description of BNZ pharmacokinetics (PK) 
in Chagas disease adult patients [79]. In others the evaluation of NFX has gained 
prominence under the promotion of Bayer, NFX producer. The use of fexinidazole, a 
nitroimidazole drug like BNZ that is being trialed for human African trypanosomiasis and 
leishmaniasis (respectively caused by T. cruzi closely related Kinetoplastid parasites T. 
brucei gambiense and T. brucei rhodensiense, and by Leishmania spp.), and of the 
antiarrhythmic drug amiodarone are also being clinically assessed for the first time 
against T. cruzi based on their anti-parasitic capacities [80,81]. These ongoing trials range 
from smaller Phase 1 to larger Phase 2 and 3 efficacy studies. There are: (1) a Phase 1 
safety, tolerability and bioavailability assessment of new NFX tablets and another Phase 
1 study to determine NFX PK in relation to dietary habits; (2) a Phase 2 study to evaluate 
different BNZ regimens (MULTIBENZ); (3) another Phase 2 study to evaluate reduced 
and intermittent BNZ regimens, either given alone or in combination with E1224 
(BENDITA); (4) two more Phase 2 studies evaluating fexinidazole to respectively 
determine dosing regimens and the minimal efficacious and safety dose; (5) a Phase 2-3 
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trial to compare safety and efficacy of NFX and BNZ (EQUITY); (6) a Phase 3 study to 
assess amiodarone, a commonly used antiarrhythmic with selective anti-T. cruzi 
properties, administered over 6 months to individuals with mild-to-moderate Chagas 
cardiomyopathy (ATTACH); (7) a Phase 3 study of a pediatric formulation of NFX 
(CHICO); and (8) a very recently added Phase 3 study to evaluate a short dose of BNZ in 
child-bearing age women (BETTY) (Table 2). 
All Phase 2 or above trials in Table 2 but CHICO involve the evaluation of drugs 
in chronically infected adult patients, and the measurement of treatment success will rely 
on molecular detection of the parasite DNA. In contrast, in CHICO, designed to assess 
NFX performance in Chagas disease infant population, the way to measure cure is 
seroconversion a yea  after treatment because this is much easier to timely occur in 
children than in adults and its readout is less ambiguous than the PCR output. All these 
studies are currently in the recruiting stage, except FEXI NCT02498782 and CHICO 
which are active but not recruiting, and BETTY that is not yet recruiting 
(https://clinicaltrials.gov). Regarding the latter, benefits of treating T. cruzi-infected 
women before pregnancy have been described by several smaller studies [22–25]. 
Hopefully BETTY´s outcome will serve to enforce treatment administration to all child-
bearing age women as soon as possible.
Expert Commentary: 500-1000 words (included in overall word count).
A huge drawback in the management of Chagas disease has traditionally been the 
lack of awareness of the disease and its impact by both health professionals and the 
patients themselves, as well as by governmental institutions with the power to dictate 
health policies. However, Chagas disease awareness is gradually increasing, so that 
efforts to combat this neglected tropical disease now need to shift in order to address its 
often insidious onset and silent clinical progression. These features currently complicate 
the access to timely diagnosis and treatment, which is also ballasted by the very limited 
resources available for research and development of improved treatment and disease 
prevention methodologies.
After so many years of neglecting Chagas disease, new efforts at R&D have the 
potential for high returns on investment. However, the R&D needs for Chagas disease are 
pervasive and span requirements for both basic and applied research, as well as new 
drugs, diagnostics and vaccines. With the ultimate goal of controlling the disease in 
endemic and non-endemic regions, the consequences of widening our understanding on 
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Chagas disease and the pathogen that causes it will have an impact on the lives of millions 
of people. For instance, research on parasite-host interactions is needed to fully 
comprehend the pathogenic processes that lead to the life-threatening symptomatology 
characteristic of chronic T. cruzi infections. Furthermore, considering that in the absence 
of treatment ~30% of those chronically infected will develop cardiac and/or digestive 
tract disruptions, studies on both parasite and host genomics (and other omics) are 
required to determine the key factors leading to the development of pathogenesis. Deeper 
understanding of the parasite biology and of its interactions with the host is fundamental 
for the discovery of safer drugs or vaccines. Another challenge is the dearth of public 
policies and advocacy that so far has mostly failed to attract requisite funding. 
Currently the most urgent needs include an expansion in clinical studies to test an 
enlarged portfolio of new drugs, together with improved biomarkers to monitor disease 
progress. There is also urgency for inexpensive and accessible point-of-care diagnostics, 
especially for mass screenings as well as for the early assessment of treatment responses. 
Their availability will widen access to treatment because they would introduce a more 
accurate picture of the disease epidemiology, as well as the ability to acknowledge cure 
upon treatment.
Five-year view
We expect that increasing awareness on the prevalence and health impact of 
Chagas disease among patients, health practitioners and political health authorities may 
eventually translate to enhanced population-based diagnostic screening and treatment 
interventions. The tools needed to facilitate this activity are being tested currently in the 
field and incorporate more practical and point-of-care diagnostics, new drugs regimens, 
and the standardization of daily clinical care routines. In addition, efforts to obtain 
biomarkers of disease prognosis and early assessment of treatment are also being 
achieved and will probably yield results soon.
Upon failure of azoles, the majority of presently ongoing Chagas disease clinical 
trials either evaluate alternative regimens of current drugs or other chemical entities (e.g., 
fexinidazole, amiodarone) with the aim to identify dosages with lower toxicity and at least 
equal efficacies compared to present chemotherapy with either benznidazole or 
nifurtimox. There is optimism that a new treatment is scheduled for Chagas disease in the 
next few years. Further complementing the new antiparasitic drugs is a new therapeutic 
biologic, a vaccine, now advancing to the clinic. However, access to these new drugs and 
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innovations will require enhanced policies and advocacy activities. In parallel, it will be 
essential to shape and disseminate pharmacovigilance protocols so that drugs 
performance can be closely monitored, and patient and healthcare provider confidence on 
these therapies promoted and maintained.
The functional deployment of counter-reference circuits fully integrated in the 
national health services will also be required to scale up the attention to Chagas disease 
patients. In this regards, improved coordination between vector control authorities and 
sanitary authorities will need strengthening in those regions with active vector 
transmission of the infection. Widespread access to diagnosis and treatment will not yield 
the desired outcome unless chances to get re-infected are minimized or eliminated. This 
approach also requires maintaining blood screening and programs to stop congenital 
transmission. An improved maternal diagnosis and treatment would in itself reduce 
congenital transmission. 
Chagas disease management and control is still a huge challenge. Success relies 
on continued involvement with key actors, including patients associations, health 
authorities at regional and national levels, governmental and non-governmental 
institutions, basic and clinical researchers, and of course financial partners.
Key issues
 Chagas disease is a neglected disease caused by the parasite Trypanosoma cruzi. It 
affects millions of people in the Americas where it has a devastating health and 
socioeconomic impact. The disease affects most those with lower resources, binding 
them to poverty and leaving them aside. It was traditionally considered a stigma, 
hidden by society and ignored by governments. Thankfully to medical researchers, 
patients’ associations and several other actors who have raised awareness and 
promoted education on the disease and its management, there has been a dramatic 
shift towards improved diagnosis, treatment and control in recent decades.
 There are highly sensitive and specific diagnostics for both the acute and the chronic 
stages of the infection. However, they are not widely implemented in many areas 
distant from reference laboratories due to logistical issues and the lack of equipped 
facilities and trained personnel. Therefore, more practical methodologies and 
algorithms should be used to provide point-of-care diagnostics prior to gaining access 
to treatment.
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 Two drugs are currently available to treat the infection: benznidazole and nifurtimox. 
Both are highly efficacious in newborns, but access to treatment generally occurs at 
the chronic stage when symptomatology arises. Due to the frequent adverse side 
effects associated to their long administration regimens, pharmacovigilance programs 
to report drugs toxicities and a better management of these in primary care 
establishments must be implemented to ensure tighter adherence to medication.
 Stronger involvement of public health institutions and authorities is fundamental to 
progress in the disease control and its adequate management. The establishment of 
counter-reference circuits integrated in national health services working plans will be 
fundamental to catalyze and scale up the attention and care of Chagas disease patients 
in endemic and non-endemic settings.
 Although great progresses in the control of vector-related transmission has been made 
in some regions, there are many where vector transmission is still active. Therefore, 
increased cooperation betw en vector control programs and medical (diagnostic and 
treatment) programs must be put on place to maximize their impact in public health.
 The role of patients’ associations must remain active and exert pressure on other 
stakeholders in order to keep up Chagas disease visibility. Patient organizations are 
at the frontline to demand attention from the responsible authorities, ensure adequate 
medical care, and highlight the potential returns on investment from R&D.
 In line with the shift on the disease awareness, the clinical research landscape has 
recently changed for the better. At present there are several clinical trials ongoing and 
their results are expected to generate improvements in diagnosis and treatment 
algorithms and policies in the near future. They may also lead to the advancement and 
licensure of new drugs, diagnostics, and vaccines. 
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1 Title: Strategies to enhance access to diagnosis and treatment for Chagas disease 
2 patients in Latin America.
3
4 Structured abstract (maximum 200 words): 
5 Introduction: Chagas disease, caused by infection with the parasite Trypanosoma cruzi, 
6 represents a huge public health problem in the Americas, where millions of people are 
7 affected. Despite the availability of two drugs against the infection (benznidazole and 
8 nifurtimox), multiple factors impede their effective usage: 1) gaps in patient and 
9 healthcare provider awareness; 2) lack of access to diagnosis; 3) drug toxicity and 
10 absence of algorithms to address adverse effects; 4) failures in drug supply and 
11 distribution; and 5) inconsistent drug efficacy against the symptomatic chronic stage. 
12 Areas covered: we review new approaches and technologies to enhance access to 
13 diagnosis and treatment as a means to reduce the disease burden. We also provide an 
14 updated picture of recently published and ongoing anti-T. cruzi drug clinical trials. 
15 Despite progress improving the research and development landscape, it is unclear 
16 whether new treatments will emerge soon. Search methodologies included multiple 
17 queries to public databases and the use of own-built libraries. 
18 Expert opinion: besides R&D, there is a major need for continue awareness and 
19 advocacy efforts by patient associations, local and national governments and 
20 international agencies. Overall health system strengthening is essential to ensure vector 
21 control commitments, and patients access to diagnosis and treatment.
22 Chagas disease, caused by infection with the parasite Trypanosoma cruzi, represents a 
23 huge public health problem in the Americas, where millions of people are affected. 
24 Despite the availability of two drugs against the infection (benznidazole and 
25 nifurtimox), multiple factors impede their effective usage: 1) gaps in patient and 
26 healthcare provider awareness; 2) lack of access to diagnosis; 3) drug toxicity and 
27 absence of treatment algorithms to address their adverse effects; 4) failures in drug 
28 supply and distribution; and 5) inconsistent drug efficacy against the symptomatic 
29 chronic stage. Here we review new approaches and technologies to enhance diagnosis 
30 and treatment algorithms as a means to reduce the disease burden. We also provide an 
31 updated picture of recently published and ongoing anti-T. cruzi drug clinical trials. 
32 Although there has been progress improving the research and development (R&D) 
33 landscape for this traditionally forgotten disease, it is unclear whether any new licensed 
34 treatments will emerge soon. Therefore, in parallel with R&D approaches we 
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35 summarize the needs to continue awareness and advocacy efforts by patient 
36 associations, local and national governments and international agencies, and why health 
37 system strengthening is essential to ensure vector control commitments, as well as 
38 patient access to diagnosis and treatment.
39
40 Keywords:  Chagas disease, comprehensive care, clinical trials, diagnosis, drug 
41 treatment, patients associations, pharmacovigilance, vector control.
42
43 Article highlights:
44  Chagas disease is a neglected disease caused by the parasite Trypanosoma cruzi (T. 
45 cruzi). It affects millions of people in the Americas where it has a devastating health 
46 and socioeconomic impact. The disease affects most those with lower resources, 
47 binding them to poverty and leaving them aside. It was traditionally considered a 
48 stigma, hidden by society and ignored by governments. Thankfully to medical 
49 researchers, patients’ associations and several other actors who have raised 
50 awareness and promoted education on the disease and its management, there has 
51 been a dramatic shift towards improved diagnosis, treatment and control in recent 
52 decades.
53  There are highly sensitive and specific diagnostics for both the acute and the chronic 
54 stages of the infection. However, they are not widely implemented in many areas 
55 distant from reference laboratories due to logistical issues and the lack of equipped 
56 facilities and trained personnel. Therefore, more practical methodologies and 
57 algorithms should be used to provide point-of-care diagnostics prior to gaining 
58 access to treatment.
59  Two drugs are currently available to treat the infection: benznidazole and 
60 nifurtimox. Both are highly efficacious in newborns, but access to treatment 
61 generally occurs at the chronic stage when symptomatology arises. Due to the 
62 frequent adverse side effects associated to their long administration regimens, 
63 pharmacovigilance programs to report drugs toxicities and a better management of 
64 these in primary care establishments must be implemented to ensure tighter 
65 adherence to medication.
66  Stronger involvement of public health institutions and authorities is fundamental to 
67 progress in the disease control and its adequate management. The establishment of 
68 counter-reference circuits integrated in national health services working plans will 
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69 be fundamental to catalyze and scale up the attention and care of Chagas disease 
70 patients in endemic and non-endemic settings.
71  Although great progresses in the control of vector-related transmission has been 
72 made in some regions, there are many where vector transmission is still active. 
73 Therefore, increased cooperation between vector control programs and medical 
74 (diagnostic and treatment) programs must be put on place to maximize their impact 
75 in public health.
76  The role of patients’ associations must remain active and exert pressure on other 
77 stakeholders in order to keep up Chagas disease visibility. Patients´ organizations 
78 are at the frontline to demand attention from the responsible authorities, ensure 
79 adequate medical care, and highlight the potential returns on investment from R&D.
80 In line with the shift on the disease awareness, the clinical research landscape has recently 
81 changed for the better. At present there are several clinical trials ongoing and their results 
82 are expected to generate improvements in diagnosis and treatment algorithms and 
83 policies in the near future. They may also lead to the advancement and licensure of new 
84 drugs, diagnostics, and vaccines.
85
86 Body of the article.
87 Expert Commentary: 500-1000 words (included in overall word count).
88 A huge drawback in the management of Chagas disease has traditionally been 
89 the lack of awareness of the disease and its impact by both health professionals and the 
90 patients themselves, as well as by governmental institutions with the power to dictate 
91 health policies. However, Chagas disease awareness is gradually increasing, so that 
92 efforts to combat this neglected tropical disease now need to shift in order to address its 
93 often insidious onset and silent clinical progression. These features currently complicate 
94 the access to timely diagnosis and treatment, which is also ballasted by the very limited 
95 resources available for research and development of improved treatment and disease 
96 prevention methodologies.
97 After so many years of neglecting Chagas disease, new efforts at R&D have the 
98 potential for high returns on investment. However, the R&D needs for Chagas disease 
99 are pervasive and span requirements for both basic and applied research, as well as new 
100 drugs, diagnostics and vaccines. With the ultimate goal of controlling the disease in 
101 endemic and non-endemic regions, the consequences of widening our understanding on 
102 Chagas disease and the pathogen that causes it will have an impact on the lives of 
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103 millions of people. For instance, research on parasite-host interactions is needed to fully 
104 comprehend the pathogenic processes that lead to the life-threatening symptomatology 
105 characteristic of chronic T. cruzi infections. Furthermore, considering that in the 
106 absence of treatment ~30% of those chronically infected will develop cardiac and/or 
107 digestive tract disruptions, studies on both parasite and host genomics (and other omics) 
108 are required to determine the key factors leading to the development of pathogenesis. 
109 Deeper understanding of the parasite biology and of its interactions with the host is 
110 fundamental for the discovery of safer drugs or vaccines. Another challenge is the 
111 dearth of public policies and advocacy that so far has mostly failed to attract requisite 
112 funding. 
113 Currently the most urgent needs include an expansion in clinical studies to test 
114 an enlarged portfolio of new drugs, together with improved biomarkers to monitor 
115 disease progress. There is also urgency for inexpensive and accessible point-of-care 
116 diagnostics, especially for mass screenings as well as for the early assessment of 
117 treatment responses. Their availability will widen access to treatment because they 
118 would introduce a more accurate picture of the disease epidemiology, as well as the 
119 ability to acknowledge cure upon treatm nt.
120
121 Five-year view
122 We expect that increasing awareness on the prevalence and health impact of 
123 Chagas disease among patients, health practitioners and political health authorities may 
124 eventually translate to enhanced population-based diagnostic screening and treatment 
125 interventions. The tools needed to facilitate this activity are being tested currently in the 
126 field and incorporate more practical and point-of-care diagnostics, new drugs regimens, 
127 and the standardization of daily clinical care routines. In addition, efforts to obtain 
128 biomarkers of disease prognosis and early assessment of treatment are also being 
129 achieved and will probably yield results soon.
130 Upon failure of azoles, the majority of presently ongoing Chagas disease clinical 
131 trials either evaluate alternative regimens of current drugs or other chemical entities 
132 (e.g., fexinidazole, amiodarone) with the aim to identify dosages with lower toxicity and 
133 at least equal efficacies compared to present chemotherapy with either benznidazole or 
134 nifurtimox. There is optimism that a new treatment is scheduled for Chagas disease in 
135 the next few years. Further complementing the new antiparasitic drugs is a new 
136 therapeutic biologic, a vaccine, now advancing to the clinic. However, access to these 
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137 new drugs and innovations will require enhanced policies and advocacy activities. In 
138 parallel, it will be essential to shape and disseminate pharmacovigilance protocols so 
139 that drugs performance can be closely monitored, and patient and healthcare provider 
140 confidence on these therapies promoted and maintained.
141 The functional deployment of counter-reference circuits fully integrated in the 
142 national health services will also be required to scale up the attention to Chagas disease 
143 patients. In this regards, improved coordination between vector control authorities and 
144 sanitary authorities will need strengthening in those regions with active vector 
145 transmission of the infection. Widespread access to diagnosis and treatment will not 
146 yield the desired outcome unless chances to get re-infected are minimized or eliminated. 
147 This approach also requires maintaining blood screening and programs to stop 
148 congenital transmission. An improved maternal diagnosis and treatment would in itself 
149 reduce congenital transmission. 
150 Chagas disease management and control is still a huge challenge. Success relies 
151 on continued involvement with key actors, including patients associations, health 
152 authorities at regional and national levels, governmental and non-governmental 
153 institutions, basic and clinical researchers, and of course financial partners.
154
155 Key issues
156  Chagas disease is a neglected disease caused by the parasite Trypanosoma cruzi. It 
157 affects millions of people in the Americas where it has a devastating health and 
158 socioeconomic impact. The disease affects most those with lower resources, binding 
159 them to poverty and leaving them aside. It was traditionally considered a stigma, 
160 hidden by society and ignored by governments. Thankfully to medical researchers, 
161 patients’ associations and several other actors who have raised awareness and 
162 promoted education on the disease and its management, there has been a dramatic 
163 shift towards improved diagnosis, treatment and control in recent decades.
164  There are highly sensitive and specific diagnostics for both the acute and the chronic 
165 stages of the infection. However, they are not widely implemented in many areas 
166 distant from reference laboratories due to logistical issues and the lack of equipped 
167 facilities and trained personnel. Therefore, more practical methodologies and 
168 algorithms should be used to provide point-of-care diagnostics prior to gaining 
169 access to treatment.
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170  Two drugs are currently available to treat the infection: benznidazole and 
171 nifurtimox. Both are highly efficacious in newborns, but access to treatment 
172 generally occurs at the chronic stage when symptomatology arises. Due to the 
173 frequent adverse side effects associated to their long administration regimens, 
174 pharmacovigilance programs to report drugs toxicities and a better management of 
175 these in primary care establishments must be implemented to ensure tighter 
176 adherence to medication.
177  Stronger involvement of public health institutions and authorities is fundamental to 
178 progress in the disease control and its adequate management. The establishment of 
179 counter-reference circuits integrated in national health services working plans will 
180 be fundamental to catalyze and scale up the attention and care of Chagas disease 
181 patients in endemic and non-endemic settings.
182  Although great progresses in the control of vector-related transmission has been 
183 made in some regions, th re are many where vector transmission is still active. 
184 Therefore, increased cooperation between vector control programs and medical 
185 (diagnostic and treatment) programs must be put on place to maximize their impact 
186 in public health.
187  The role of patients’ associations must remain active and exert pressure on other 
188 stakeholders in order to keep up Chagas disease visibility. Patient organizations are 
189 at the frontline to demand attention from the responsible authorities, ensure adequate 
190 medical care, and highlight the potential returns on investment from R&D.
191  In line with the shift on the disease awareness, the clinical research landscape has 
192 recently changed for the better. At present there are several clinical trials ongoing 
193 and their results are expected to generate improvements in diagnosis and treatment 
194 algorithms and policies in the near future. They may also lead to the advancement 
195 and licensure of new drugs, diagnostics, and vaccines. 
196
197 1. Introduction.
198 Chagas disease, or American trypansosomiasis, is caused by the protozoan 
199 parasite Trypanosoma cruzi (T. cruzi) and remains one of the most deadly and 
200 intractable neglected tropical diseases (NTDs) in the Western Hemisphere [1].  Updated 
201 information from the Global Burden of Disease Study (GBD) 2016 indicates that 7,100 
202 people die from Chagas disease annually, roughly the same number of Chagas disease-
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203 related deaths that occurred a decade previously [2]. However, these numbers may 
204 represent highly conservative estimates with further findings that as many as 200,000 
205 people living with T. cruzi infection may die over the next five years [3]. The GBD 
206 2016 also finds that 7.2 million now live with Chagas disease, while 180,000 new T. 
207 cruzi infections occur annually [4].
208 Beyond its horrific disease burden and contribution to infectious disease 
209 mortality, there is a profoundly disturbing social impact dimension to Chagas disease 
210 related to its importance as a health disparity. Today, tens of thousands of people face a 
211 death sentence from their T. cruzi infection due to Chagasic cardiomyopathy, which 
212 could be prevented by timely access to diagnosis and anti-parasitic treatment with one 
213 of two nitroheterocyclic drugs – benznidazole (BNZ) and nifurtimox (NFX). Fueling a 
214 growing outrage from the global health community is the finding that approximately 
215 90% of people infected with T. cruzi infection now live in Latin America’s three 
216 wealthiest economies: Argentina, Brazil, and Mexico. In the United States of America 
217 (USA), the richest country of the continent and main destiny of those looking for a 
218 better future, there are at least 200,000 immigrants from Latin America living with 
219 Chagas disease with limited or no acc ss to treatment [5,6]. Furthermore, in Europe 
220 there are around 120,000 immigrants from Latin America living with Chagas diseases 
221 with a disparity of situations regarding access to care and treatment [7,8].
222 The overwhelming majority of Chagas disease sufferers are unable to gain 
223 access to diagnosis and treatment, not only because they are poor, but also because 
224 governmental leaders are either uninformed or uninterested. For example, it is 
225 noteworthy that the registration of BNZ for the treatment of pediatric Chagas disease in 
226 the USA has not been approved until very recently [9]. Documenting such assertions is 
227 not easy and seeking solutions to diagnosis and treatment access are not straightforward 
228 endeavors. In Mexico, for example, there are almost one million people living with 
229 Chagas disease, although even that number may represent a profound underestimate 
230 [10]. Yet, only 3,013 T. cruzi infection cases were registered nationally between the 
231 years 2007 and 2011, less than 1% of the actual number of people affected with the 
232 disease [11]. A similar situation has been documented for the USA [12] and also likely 
233 holds true across the Americas. We are facing a situation where less than 1% of Chagas 
234 disease patients have access to timely and appropriate diagnosis and treatment [13,14].
235 Limiting access to essential medicines also has important implications for new 
236 research and development (R&D) related to therapeutic interventions. An exciting 
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237 development on this front is a new orally bioavailable nitroheteorcyclic drug, 
238 fexinidazole, which is also effective against human African trypanosomiasis [15]. 
239 Additional drugs are also under development, as well as there are Chagas disease 
240 vaccine (immunotherapeutic) candidates at pre-clinical stage [16]. In this respect, the 
241 Texas Children’s Hospital Center for Vaccine Development, a Product Development 
242 Partnership, is exploring an approach that links therapeutic vaccination to 
243 pharmacotherapy [17]. However, any R&D successes must still face a formidable 
244 gauntlet of truncated and mostly failed global access mechanisms. Similar forces are a 
245 barrier for access to new and innovative diagnostics [18].
246 Here we report on some of the major hurdles that currently block access to the 
247 diagnosis and treatment of Chagas disease. The problems include both scientific and 
248 socioeconomic obstacles. This paper aims to elucidate the challenges they pose and 
249 offer solutions.
250
251 2. The need of more practical and useful diagnostics.
252 The poor access rate to Chagas disease therapeutic treatments has its roots in the 
253 clinical nature of the disease itself and its silent progression from the mostly 
254 asymptomatic acute stage into the symptomatic chronic one [1]. Unfortunately, 
255 biomarkers of disease progression and standardized tools to  determine early response-
256 to-treatment are yet unavailable, which greatly complicates the prognosis and follow-up 
257 of patients [19].  
258 Treatment administration, as in any other disease, needs to be preceded by an 
259 adequate diagnosis. In the case of Chagas disease, when a clinical diagnosis is achieved, 
260 tissue disruptions might already be too advanced for a chemotherapeutic intervention. 
261 Therefore, parasite detection must be sought before the onset of overt symptomatology. 
262 In the acute infection stage, for instance upon congenital transmission of the parasite, 
263 parasitemia can be detected by direct microscopic observation [1]. However, this stage 
264 is short lasting and generally goes unnoticed as there are often no symptoms at all. 
265 Approximately 30% of these infected individuals will progress to evidence of either 
266 Chagasic cardiac or gastrointestinal disease. Those without clinical evidence of disease 
267 are said to be at the indeterminate stage, whereas those with cardiac or gastrointestinal 
268 involvement are at the determinate stage. The development of life-threatening heart 
269 and/or digestive tract disruptions, which can be massive and are called mega-
270 syndromes, occurs in the long lasting chronic stage that follows [1]. 
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271 In both indeterminate and determinate Chagasic patients, parasitemia is typically 
272 low and intermittent and the diagnosis of the infection is made by means of indirect 
273 serological tests, like enzyme-linked immunosorbent assays (ELISAs). This is possible 
274 because high levels of parasite-specific immunoglobulins are produced upon T. cruzi 
275 infection (Figure 1). Anti-T. cruzi type G immunoglobulins (IgGs) levels remain above 
276 detection thresholds for many years, which is advantageous for the serological diagnosis 
277 of the infection (Figure 1). However, it turns out to be an inconvenience for a serology-
278 based assessment of drug responses as it can take several years for them to revert after 
279 the administration of treatment [20].  Another issue to take into account in the diagnosis 
280 of the infection is the wide genetic variability of the parasite, which encompasses seven 
281 different genotypes grouped in Discrete Typing Units (DTUs) [21]. A role of the 
282 parasite and host genetics interplay has been suggested in relation to the sensibility to 
283 treatment of the distinct isolates, the pathological signatures of the infection, and also in 
284 the anti-T. cruzi immune response [21].  
285 Some studies indicate that treatment interventions while patients are in the 
286 indeterminate or early determinate stages are critically important in order to prevent 
287 advanced disease progression. In contrast, from the multi-centered BENEFIT trial to 
288 evaluate benznidazole BNZ efficacy it was found that patients with significant cardiac 
289 involvement progressed to advanced disease or even died despite receiving specific 
290 antiparasitic chemotherapy [3,21]. Currently a Kushnir grading system is in place to 
291 differentiate people with early-stage (grades I-II) versus late stage (Kushnir III-IV) 
292 determinant cardiac disease [1]. Treatment  of patients with Kushnir grades III-IV was 
293 not encouraged previously [1], a finding that appears to hold up in light of the recent 
294 BENEFIT findings. Currently several classifications (for instance AHCC, or Kuschnir´s 
295 modified) are in place to differentiate people with early-stage (grades A-B or 0-I 
296 respectively) versus late stage (grades C-D or II-III respectively) cardiac disease. 
297 Treatment  of patients with grades C-D or II-III was not encouraged previously [1], a 
298 finding that appears to hold up in light of the recent BENEFIT findings. 
299 These findings highlight the importance of identifying both indeterminate 
300 patients with Chagas disease, and possibly those with AHCC grades A-B or modified 
301 Kuschnir grades 0-I too, since they might be successfully treated with antiparasitic 
302 therapy if they were captured during  population-wide screening campaigns [3]. In this 
303 way, it would be possible to identify and treat chronically infected people before they 
304 develop the symptomatology. Women at child-bearing age and newborns should receive 
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305 special attention because the treatment of mothers-to-be has been shown to largely 
306 reduce the transmission rate [23–26], and the efficacy and tolerability of current drugs 
307 by infected newborns is ~100% [1]. Moreover, health economics studies evaluating 
308 Chagas disease surveillance in endemic and non-endemic settings indicate that 
309 widespread screening would be highly cost-effective [27–30]. In the two disease 
310 scenarios studied, congenital (acute infection transmitted by chronically infected 
311 mothers) and indeterminate (chronic asymptomatic stage), mass screening would save 
312 health costs even at T. cruzi prevalence rates as low as 0.9% or 0.05% respectively (in 
313 fact estimated in the a non-endemic setting) [2627,2829].
314 Due to the very limited resources available for Chagas disease management, and 
315 echoing the answers provided by Latin American experts enquired by Picado et al. [18], 
316 efforts should focus on making widely available point-of-care (PoC) tests to diagnose 
317 congenital transmission and indeterminate chronic patients [18]. However, if we want to 
318 enable generalized Chagas dis ase diagnosis, there is an urgent need of more practical 
319 diagnostic reagents and kits. Availability of easy-to-use tools for the early assessment of 
320 treatment response would also be highly valuable to promote and support the 
321 administration of drugs against the infection. In this regards, there are some biomarkers 
322 under research [19], but the evaluation of anti-T. cruzi drug responses yet relies on the 
323 molecular amplification of the parasite DNA from periphery blood obtained at distinct 
324 times post-treatment. Unfortunately, its associated high costs and technical requirements 
325 restrict its use to the context of well-funded clinical trials [31].
326
327 2.1. Current Chagas disease diagnostics are impractical in many regions.
328 Regarding acute stage diagnostics, classical parasitological methods 
329 (micromethod, hemoculture and xenodiagnoses) are microscopy-based and rely on 
330 finding motile trypomastigotes in blood, thus they provide both low sensitivity and 
331 specificity. Due to their poor performance, current algorithm to diagnose congenital 
332 transmission involves two micromethods (at birth and at 1-2 months of age), and a 
333 further confirmatory serological test once mother-derived IgGs have waned at infant´s 
334 8-12 months of age [32]. This has two major drawbacks: a very high loss-to-treatment 
335 risk during pediatric follow up, and the reduction of drug efficacies the longer the 
336 treatment is delayed [32]. Molecular amplification of T. cruzi DNA, either by 
337 conventional polymerase chain reaction (PCR) or by quantitative PCR (qPCR), has 
338 been shown to be more sensitive and specific than classical parasitological techniques 
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339 [20]. Several laboratories have worked on the standardization of the techniques so that 
340 their outcomes can be comparable and implemented in clinic-based laboratories [20]. 
341 But molecular biology laboratories are expensive to mount and maintain, plus they 
342 require highly trained personnel to run them. Therefore, despite its very good 
343 performance, molecular detection is not generally used beyond regional or national 
344 reference laboratories in endemic regions.
345 In relation to the current chronic stage diagnostics, conventional serological tests 
346 (like ELISAs, indirect immune-fluorescence or indirect hemagglutination assays) use 
347 serum or plasma samples that entail venous extraction and blood segregation by 
348 centrifugation, and they require a cold chain to preserve the test reagents and the 
349 samples. Moreover, due to the parasite´s antigenic diversity, the advice from the World 
350 Health Organization (WHO) is to run two tests based on distinct antigenic sets and if 
351 their outcomes are not concurrent, to employ a third technique [14]. This algorithm is 
352 costly, and it requires equipm nt and resources that are usually not available in many 
353 laboratories of endemic regions. Furthermore, the turnaround of results to the patient 
354 can take several weeks, which involves a high risk of losing contact with the patient for 
355 treatment.
356
357 2.2. What solutions could be implemented?
358 Fortunately, recent technological advancements are procuring solutions to 
359 overcome the limitations mentioned above. We will outline them separately considering 
360 first those for the diagnosis of acute stage and then those for the diagnosis of chronic 
361 Chagas disease.
362 In recent years, isothermal amplification methods that do not require expensive 
363 equipment (such as thermocyclers or gel visualization systems) and are easier to 
364 perform than PCR assays have been developed for the molecular detection of several 
365 NTDs [20]. At present, a prototype of Loop isothermal AMPlification for T. cruzi-DNA 
366 (LAMP, Eiken Co., Japan) has been tested with clinical samples and shown to have a 
367 comparable performance to qPCR with blood-EDTA samples [33]. Another LAMP test 
368 developed in house by Rivero et al. [34] has also been shown to provide a comparable 
369 performance to current congenital transmission algorithm. LAMP is based on a 
370 microbiological DNA polymerase that works at a constant temperature of 65 ºC for 45 
371 minutes with a set of 4 to 6 complex primer sequences to provide a highly sensitive and 
372 specific amplification [35]. LAMP readout is qualitative and the results can be naked 
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373 eye visualized in a short time given a probe (e.g. calcein) is added to the reaction mix. If 
374 a digital fluorimeter is used (e.g. Genie III) the reading can even be semi-quantitative 
375 [33]. Notably, in EIKENEiken´s T. cruzi-LAMP prototype, reagents are provided dried 
376 out in the lids of the reaction tubes which allow a ready-to-use format and a much 
377 desirable room temperature storage [33]. More recently, a Recombinase Polymerase 
378 Assay (RPA), which even requires a lower amplification temperature and shorter 
379 amplification time (40 ºC for 30 min) than LAMP, has been tested with samples from 
380 naturally T. cruzi-infected dogs [36]. This RPA has been coupled to a lateral flow strip 
381 for results reading and it was shown to provide excellent agreement with qPCR results 
382 [36]. There are RPAs for the detection of other NTDs [36,37,38], so it could also be 
383 very useful for Chagas disease molecular diagnosis.
384 For the serological detection of T. cruzi-specific IgGs, rapid diagnostic tests 
385 (RDTs) have been commercially developed during the last two decades [3839,3940]. 
386 RDTs have clear advantages over conventional serology, as they can be stored at room 
387 temperature, use a very small volume (5-25 µl) of finger pricked whole blood, have an 
388 easy-to-run and read cassette format, and provide a fast turnaround of results (less than 
389 45 minutes) [40]. Several studies now support their implementation as they have been 
390 extensively validated against conventional tests [41–43]. For instance, a RDT is 
391 currently used for primary screening of chronic Chagas disease in Bolivia [3941]. 
392 Nonetheless, following the WHO guidelines of two-tests concordance, confirmation of 
393 that RDT primary result must yet be made with a conventional serological test [14].  
394 Such recommendations reduce the advantages of RDTs.
395 With the aim to fully exploit RDTs advantages and to determine whether they 
396 can substitute conventional tests, combinatory use of two RDTs has been proposed [41]. 
397 So far, in a proof-of-concept study performed in the city of Sucre (Bolivia), perfect 
398 agreement between the two RDTs used was observed, and their sensitivity and 
399 specificity in comparison with three conventional tests was 100% and 99.3%, 
400 respectively [4041]. However, despite a promising performance in Bolivia [4041,4243], 
401 RDTs have not worked so well when they have been used in other geographical regions 
402 [44]. This might be related to the high prevalence of the disease in Bolivia, which may 
403 allow an easier detection, or to the fact that the parasite strains used to produce the 
404 RDTs antigens are those circulating in Bolivia. In any case, until more results from 
405 different epidemiological areas are available, preliminary geographical testing of the 
406 RDTs performance has been proposed before using them in a particular region [44]. In 
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407 view of the advantages they bring versus conventional tests, RDTs implementation for 
408 Chagas disease surveillance should be evaluated at larger scales. 
409
410 3. Treatment of Chagas disease, and issues related to it.
411 3.1. Drug regimens.
412 Evidence about the benefits of Chagas disease treatment, together with a 
413 growing understanding of the pathogenesis of the disease, led to the paradigm that all T. 
414 cruzi-seropositive patients should receive treatment with anti-T. cruzi drugs [45]. The 
415 recently published results of the SaMi-Trop cohort study further reaffirm this statement 
416 as they demonstrate a beneficial effect of BNZ in reducing the cardiac clinical 
417 progression of chronic Chagas disease patients [46]. Therefore, anti-trypanosomatid 
418 treatment should be provided to all T. cruzi-infected people who do not present with  
419 advanced cardiac complications (Kuschnir grades III-IV), as by then clinical 
420 manifestations might not be improved [47]. Nonetheless, access to treatment confronts 
421 important limitations. BNZ and NFX, the only drugs available for T. cruzi infection, 
422 exhibit reduced efficacy during the chronic stage of the disease, and require a long 
423 period of administration which causes fr quent unwanted drug-related adverse reactions 
424 (ADRs) [48–50]. Furthermore, variable drug susceptibility has been already described 
425 among distinct T. cruzi strains [51]. In this context, there is an urgent need for more 
426 efficacious and safer drugs or drugs´ regimens, in particular for the treatment of the 
427 chronic stage of the infection.
428 One alternative is the reduction of the BNZ dose and/or schedule in order to 
429 improve safety and adherence to treatment; an approach that is supported by clinical and 
430 experimental data. In a pilot study Álvarez et al. [52] assessed a new scheme of BNZ 
431 administration in a small cohort of chronic Chagas disease patients treated with 
432 intermittent doses of BNZ at 5 mg/kg/day every 5 days for a total of 60 days. The study 
433 showed a satisfactory safety profile, with low rates of treatment suspension and 
434 treatment failure [52]. Furthermore, an experimental study using a mouse model of 
435 chronic T. cruzi infection demonstrated the effectiveness of an intermittent scheme of 
436 BNZ administered every 5 days for 40 days [53]. These findings support the 
437 intermittent administration of BNZ as a new dosage schedule, but further research to 
438 confirm its efficacy by long-term assessment of larger cohorts is needed. Another 
439 therapeutic option under investigation is the co-administration of an immunotherapeutic 
440 (vaccine) treatment and BNZ. In this regards, enhancement of a T. cruzi-specific 
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441 immune response has been shown to contribute to support the efficacy of reduced BNZ 
442 dosages in a mouse model of acute T. cruzi infection [17].
443
444 3.2. Drug availability.
445 Drug access is still a huge problem in some endemic areas [13]. BNZ, generally 
446 the first line therapy for Chagas disease, is part of the WHO List of Essential Medicines 
447 [54]. It was produced during more than 40 years by Roche (Basilea, Switzerland), 
448 which transferred its production rights to Laboratório Farmacêutico de Pernambuco 
449 (LAFEPE), a Brazilian public enterprise, at the end of the twentieth century. Sadly, 
450 BNZ production and distribution by LAFEPE failed to meet expectations in terms of 
451 meeting supply and demand requirements and in 2011 an important shortage of the drug 
452 occurred. It lasted 1.5 years and left thousands of patients without treatment worldwide 
453 [13,5355]. This fact led to the development of a Private-Public Partnership in Argentina 
454 involving Maprimed (for the synthesis of the drug) and ELEA (for its development and 
455 production), to promote equitable availability of BNZ [56]. Since 2012, this Argentinian 
456 Partnership has worked to guarantee the availability of the drug, distributing BNZ to the 
457 countries in the region [56]. NFX, which is mostly used as the second line treatment 
458 option, is produced and donated by the pharmaceutical company Bayer, and distributed 
459 through the Pan-American Health Organization (PAHO) Strategic Fund [57]. Recently, 
460 a NFX produced by Gador has also been registered in Argentina. Definitely, a regular, 
461 safe and accessible production of these two anti-parasitic drugs is necessary to 
462 guarantee the treatment to diagnosed patients, and the access to drugs has to be ensured 
463 in adequate quantity, quality, location and timing.
464
465 3.3. Pharmacovigilance.
466 A major limitation of current Chagas disease treatments is the onset of Adverse 
467 Drug Reactions (ADRs), which may lead to poor medication adherence, and cause 
468 thereby therapeutic failure or ineffective treatment [4648-4850]. ADRs are defined as 
469 "an appreciably harmful or unpleasant reaction, resulting from an intervention related to 
470 the use of a medicinal product, which predicts hazard from future administration and 
471 warrants prevention or specific treatment, or alteration of the dosage regimen, or 
472 withdrawal of the product” [58]. The most commonly observed ADRs related to BNZ 
473 are headache, dermatological manifestations and gastrointestinal symptoms 
474 [4749,4850]. Concerning NFX, digestive symptoms are the most frequent [4648]. 
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475 Nevertheless, with an adequate clinical management most of the patients are able to 
476 finish treatment in the advent of ADRs [4749]. Close medical follow-up, adequate 
477 monitoring of ADRs and implementation of robust pharmacovigilance systems are 
478 essential factors to avoid patient abandonment and achieve therapeutic success.
479 Although pharmacovigilance is crucial, it is still a neglected area. Latin-
480 American countries are making important efforts to report ADRs, but these activities are 
481 recent and need reinforcement [5859,5960]. Results of an unpublished study conducted 
482 by Cortes-Serra et al. in Bolivia during 2016 indicate that 35.4% of the total patients 
483 treated for Chagas disease in fourteen healthcare centers of the department of 
484 Cochabamba suffered ADRs related to it. From all ADRs classified as moderate or 
485 severe (25% of the total ADRs registered), only about half of them (51.43%) were 
486 reported to the Bolivian Pharmacovigilance system [61]. This data illustrates the 
487 urgency of implementing policies to promote training in pharmacovigilance to all 
488 healthcare professionals, as well as strictly recommend the follow-up on drug 
489 monitoring and ADR reporting. Altogether, these features are fundamental to achieve 
490 strong and consolidated ADR reporting systems, which will improve patient safety, 
491 drug efficacy and adherence to treatment. 
492
493 4. Patients´ comprehensive care: reference and counter-reference circuits.
494 With less than 1% people treated [13,14], and an economic burden of $7.19 
495 billion per year and $188.80 billion per lifetime [62], Chagas disease remains neglected 
496 despite the efforts performed by several institutions focused on development and 
497 research [13]. Migratory flows have changed the epidemiology of the disease that is 
498 now emerging in some non-endemic countries [7]. During the last decades, 
499 collaboration and knowledge transfer between institutions from endemic (CEADES, 
500 Bolivia) and non-endemic countries (ISGlobal, Spain) has been strategic to build 
501 attention models for the Chagas disease patient. Such models could be scaled-up by 
502 national health systems in endemic and non-endemic countries in order to expand 
503 Chagas disease healthcare to people living in areas with limited access to health (e.g. 
504 rural areas in endemic countries) or to vulnerable populations (e.g. migrants in endemic 
505 and non-endemic countries).
506
507 4.1. The Platform for integral care of Chagas disease patients.
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508 The work made by this Platform in recent years have produced a quantitative 
509 and qualitative improvement in the healthcare provided to Chagas disease patients in 
510 Bolivia, but this improvement certainly needs to be strengthened. The experience gained 
511 with the Platform in the country has shown that the implementation of specialized 
512 centers to manage people at risk of having Chagas disease is highly effective, both 
513 based on the percentage (and number) of people diagnosed with the infection, and 
514 amongst them, those who received and completed treatment [63]. This vertical strategy 
515 has been essential to design the attention model for patients with Chagas, making the 
516 medical assistance to these people look like a normalized and necessary action [63]. 
517 Nevertheless, the sustainability of such model ultimately depends on continuously 
518 securing external funds, which greatly complicates its expansion to larger geographical 
519 levels, like national coverage by the national health system (Figure 2).
520
521 4.2. Vertical-to-horizontal healthcare model transition.
522 In order to have a higher impact in terms of diagnosis and treatment coverage, as 
523 well as to ensure the sustainability for the model of care of Chagas disease patients 
524 already installed, it is mandatory to s arch for a comprehensive horizontal strategy 
525 together with local higher level entities of the public health system. In fact, based on 
526 WHO recommendations, the strategy to include the Chagas disease attention roadmap 
527 as part of the regular activities of all healthcare levels seems to be the most appropriate 
528 approach [64].
529 Simplifying the vertical Chagas disease model of healthcare to more realistic 
530 protocols established together with the national health institutions has allowed the 
531 improvement of healthcare access for people at risk of having the disease living in 
532 remote areas of an endemic country [63]. Researchers at ISGlobal (authors of this 
533 review) have yet unpublished data which demonstrate that the health coverage, in terms 
534 of patients diagnosed and treated in the selected area in which the project has expanded 
535 its activity, was five times higher in the three years following the horizontal 
536 comprehensive care model than the number of people covered in the five previous years 
537 with the vertical strategy (Pinazo et al., unpublished).
538 So far, the outcome of the vertical-to-horizontal healthcare model transition 
539 highlight that it could be worthy to replicate and/or adapt it to other regions or 
540 countries. The first step would be to coordinate with local health authorities at different 
541 levels in order to design an appropriate strategy. For the implementation of a healthcare 
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542 model, the identification of interested health workers is a key issue. Even if it is 
543 simplified, a strategy to offer a comprehensive care for people at risk of suffering from 
544 Chagas disease should include: (a) specific training of health workers on the disease 
545 management; and (b) a strategy to increase the demand of the civil society, based on 
546 promotional and educational community activities. In this regard, the establishment of 
547 referral and counter-referral circuits tailored to each epidemiological and logistic 
548 situation is highly relevant, even in nearby areas.
549
550 4.3. Requirements for the expansion of the Chagas disease healthcare model.
551 Referral and counter-referral circuits, in terms of patients and samples for 
552 diagnosis or any othe  test, should include different healthcare levels to cover different 
553 levels of complexity in terms of care. The specialized centers in which the model of care 
554 has been rehearsed in Bolivia are key towards organizing these circuits, as well as to act 
555 as reference centers for complicated cases and to accompany the doubts and the 
556 continuing education of health professionals from primary care centers. This is 
557 particularly important in health systems where there is often a fast renewal of healthcare 
558 personnel. Another crucial point to make sustainable a comprehensive horizontal 
559 strategy against Chagas disease is to promote an inter-sectorial collaboration with vector 
560 control authorities (promoters of house refurbishment, disinfestation programs,...) and 
561 the educational system itself. Vector control interventions are fundamental to halt 
562 vector-dependent transmission and enable an enhanced drug control of the cases. 
563 Whereas educational activities to widen the population knowledge and perception of the 
564 disease, its impact, and treatment possibilities are crucial, because producing changes in 
565 beliefs, attitudes, and behaviors on both medical staff and patients still stands as one of 
566 the major challenges that must be faced when dealing with Chagas disease. All these 
567 measures have a role to play in order to consolidate the successful management of the 
568 disease.
569 On the other hand, lessons learned from the primary healthcare network have 
570 shown that it is mandatory to ensure the supervision of the circuits and surveillance the 
571 quality of the process, tasks that should be carried out by the national health system 
572 responsible personnel in duty. Political engagement at this point is mandatory to 
573 contribute to a better control of the disease as a Public Health problem. In this context, 
574 it is important to respect the capability of local health institutions, agreeing with them 
575 timelines and a progressive increase of the number of people diagnosed and treated, in 
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576 order to answer adequately to people’s demands. It must be noted that external factors 
577 like the poor availability of drugs for Chagas disease treatment have a sourly negative 
578 impact on any planning.
579
580 5. Patients treatment in relationship with vector control.
581 Access to diagnosis and treatment of Chagas disease in areas with active vector 
582 transmission requires a multidisciplinary approach. It involves the participation of 
583 players from several areas of expertise and different government sectors, from vector 
584 control authorities to health service providers, including primary healthcare [65].
585 Following the advice from the PAHO, intergovernmental regional initiatives 
586 were created at the end of the twentieth century and beginning of the twenty first 
587 century to establish supranational levels of action to bolster and monitor the 
588 implementation of activities to prevent, control, diagnose and treat Chagas disease in 
589 Latin America. These initiatives were started by Southern Cone countries in 1991, and 
590 then followed by Andean countries and Central American countries in 1997 and 
591 Amazonian countries in 2004 [6566,6667]. Despite these efforts, it is evident that in the 
592 region there was, and still is, a breach between the programs for vector control and the 
593 areas that are responsible for providing universal health care (including diagnosis and 
594 etiological treatment) [68].
595 It is important to consider that although policies related to the primary 
596 prevention of Chagas disease are defined at the national level, primary healthcare 
597 attention for the patient is the responsibility of the provincial/departmental or 
598 municipal/local entities [69]. Often times, these final effectors of national policies have 
599 little or no relation/communication with the national entity and are sometimes even 
600 unaware of the policies themselves. For example, suggestion of treatment of the 
601 infection by T. cruzi for postpartum women and their newborns, and the mandatory 
602 treatment for women of childbearing age and children under the age of one with Chagas 
603 disease that are in the national or supranational norms [32], make no specific mention of 
604 which protocols need to be applied with respect to vector surveillance in the houses of 
605 those patients living  in endemic areas with active vector transmission. However, recent 
606 public health interventions have shown that activities related to access to diagnosis or 
607 treatment of the disease are usually implemented and promoted by those responsible for 
608 vector control programs [70]. Thus, without consideration of the need of appropriate 
609 structures and circuits (i.e. access to an adequate laboratory for diagnosis or presence of 
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610 anti-trypanosomal drugs), which are not usually present in rural areas, one of the main 
611 actions needed is to establish and/or strengthen the link between vector control 
612 programs and the health system providers [70]. Thereafter, following a stepwise 
613 approach, another action to accomplish would be to provide technical recommendations 
614 to establish criteria for categorizing the risk of vector transmission status in an endemic 
615 area. With that information available, it could be possible to explicitly detail under 
616 which conditions Chagas disease diagnosis and treatment has to be made mandatory in 
617 the area for the entire population, or segments of it (i.e. women at childbearing age, 
618 newborns). Finally, a most desired third action would definitely be to integrate the 
619 procedures for disease diagnosis and treatment within the health system as a transversal 
620 program.
621 Nowadays there are already a few experiences that have been able to coordinate 
622 vector control actions together with diagnosis and treatment in a successful manner [71, 
623 72]. These could serve as proof-of-concept strategies for integral interventions to build 
624 on, improve and replicate. As an example, the experience of Fundación Mundo Sano, 
625 with direct and uninterrupted action in the field since 2002, is worth mentioning. Its 
626 integral program includes vector control and sanitary improvement of rural houses in 
627 the Department of General Taboada (Santiago del Estero, Argentina). In 2015, after 13 
628 years of vector surveillance and control, Mundo Sano was able to install two doctors’ 
629 offices dedicated to the diagnosis and treatment of Chagas disease together with local 
630 institutions, one in Añatuya City and another one in Colonia Dora. Since then, they have 
631 been struggling with the problems of having a mono-disease health service in a 
632 community that did not demand treatment. Despite the difficulties, after almost three 
633 years of implementation, the amount of people diagnosed and treated begun to increase. 
634 The work from these two Chagas disease specific offices was integrated to the local 
635 hospital of Añatuya in 2018, thus reaching a higher amount of T. cruzi-infected 
636 individuals derived from obstetrics, gynecology and cardiology services in addition to 
637 those attending the offices from spontaneous demand. In the same line, the Platform for 
638 the Integral Care of Chagas disease Patients was settled in Bolivia in 2009. Initially in 
639 the province of Cochabamba in the center of the country, the Platform now works also 
640 in municipalities of the provinces of Chuquisaca and Tarija [63]. Each experience, 
641 proposal or pilot study must be evaluated objectively in order to improve and multiply 
642 its impact, avoiding a future with a new inequality: one were those affected by the 
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643 disease will have access to health depending on whether they live in an endemic or non-
644 endemic area.
645
646 6. The role of patients’ associations.
647 Similarly to what happens with other NTDs programs to promote scaling up of 
648 healthcare interventions, strategies towards the control of Chagas disease often confront 
649 with structural weaknesses of the health systems in which they aim to be integrated [73–
650 75]. Therefore, more effective strategies to strengthen those health systems are required 
651 to ensure a sustainable integration of the required health innovations within them. 
652 Importantly, these strategies need to incorporate the patients´ perspective in order to 
653 overcome key access barriers [13,14,75]. Barriers that nowadays still hinder the access 
654 to diagnosis and treatment, barriers impeding a better health care.
655 In recent years, sev ral associations of Chagas disease patients have emerged 
656 and joined in a Federation of Associations whose purposes are: (i) to increase the 
657 visibility of the disease at all levels as well as of its overwhelming impact in the 
658 patients´ health status; and (ii) to promote a more active role of the people affected by 
659 the disease in the decision-making processes. But these associations face many 
660 difficulties (dispersion of objectives, multiplicity of voices with different requirements, 
661 little real mobilization in many countries, and lack of resources) to achieve their 
662 objective of having an effective role in the health policies makings of their countries.
663 The WHO global strategy on integral health services centered on people could 
664 be a way through which these associations can play an important practical role [77]. In 
665 fact one of the goals of such program is to empower individuals, families and 
666 communities by including in it some well-known activities led by patients such as 
667 community education, groups of patients for mutual support, expert patients to engage 
668 and help others, etc. [77]. In addition, this WHO program goes beyond a single disease 
669 and has the virtue of encompassing other actors with decisive roles in health systems 
670 performance, like governmental policy-makers, municipalities, donors, and providers. 
671 Overall, the strategy is thus envisaged to allow the community and patients to 
672 actively participate in the decision-making process, together with other involved actors, 
673 in issues regarding their health. By doing so, they also play a role on the way the health 
674 system is organized, for instance ensuring that community and primary healthcare are 
675 prioritized. Therefore, patients associations should look after the implementation and 
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676 compliance with this WHO strategy as it underlies the activities they are already taking 
677 on.
678
679 7. The R&D Agenda: clinical trials for new drugs or new strategies of treatment 
680 with current drugs.
681 7.1. Results from recently completed trials.
682 Upon the questioned efficacy of currently available therapies (BNZ and NFX) 
683 against the chronic symptomatic stage of the disease, clinical testing of new drugs 
684 and/or of new regimens of BNZ and NFX is being pursued. Nonetheless, some major 
685 obstacles are in the way to getting more adequate treatments, including the poor 
686 understanding of the infection pathophysiology leading to the disease clinical 
687 progression, and the lack of biomarkers to determine prognosis and cure (see review by 
688 Pinazo et al., [19]). Particularly the latter hinders the follow-up of treated patients both 
689 in the daily clinic and in clinical trials. At present, an absence of molecular 
690 amplification of T. cruzi DNA from periphery blood is used as surrogate of “treatment 
691 success”. But this approach is far from optimal, especially at the chronic stage of the 
692 disease when the parasitemia is low and intermittent. A negative result obtained at a 
693 determined time point does not exclude the possibility that a positive one will be 
694 obtained in the next visit. A false-negative PCR, i.e., a negative PCR result (“treatment 
695 success” event) in the patient follow up is then less informative than a positive 
696 determination, as this one will indeed define a case of treatment failure.   
697 Despite this limitation, several clinical trials have been completed in the last 
698 years, and there are several more currently ongoing. This advance represents a major 
699 shift in the research landscape of this historically forgotten NTD. The vast majority of 
700 the performed trials have been Phase 2 randomized, multi-centric, double-blinded, 
701 efficacy and safety studies to evaluate oral dosage schemes for the treatment of adult 
702 patients at indeterminate (asymptomatic) chronic stage (see Table 1). Amongst them, 
703 CHAGASAZOL [78], STOP CHAGAS [79] and E1224 [31] have evaluated for the first 
704 time two triazole anti-fungal drugs (posaconazole (POS), and the ravuconazole 
705 precursor E1224) for their anti-T. cruzi properties. In addition, the BENEFIT trial that 
706 evaluated the use of BNZ for chronic stage treatment must also be highlighted as it has 
707 been the largest Phase 3 Chagas disease trial performed so far [47].
708 CHAGASAZOL and E1224 trials entailed a direct comparison of POS and 
709 E1224 monotherapy at a high and a low dose to a BNZ standard dosage group (5 
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710 mg/kg/day orally divided in two daily doses for 60 days) [3031,7778]. In addition to 
711 monotherapy branches, STOP CHAGAS trial also included a study group that received 
712 POS and BNZ as combined therapy [79]. In the latter, treatment success was defined as 
713 a negative PCR value at the day 180 follow-up visit [79], whereas parasitological cure 
714 in CHAGASAZOL was determined by a negative PCR result at 12 months follow-up 
715 [78]. The most stringent success criteria was that of E1224 trial, which involved serial 
716 negative PCR results (3 negative PCR results from 3 samples collected over 7 days) at 
717 65 days after end of treatment and a further negative PCR outcome at 12 months follow-
718 up [31]. 
719 Although both POS and E1224 drugs showed good safety and efficacy profiles 
720 at end of treatment in the three studies, the suppressive effect on parasite clearance after 
721 12 months was much reduced in comparison to BNZ, which showed early and sustained 
722 efficacy until 12 months of follow-up (Table 1). Thus, neither POS nor E1224 were as 
723 good as BNZ and could not substitute it as monotherapies.
724 In the BENEFIT trial, the treatment response was evaluated in a sub-group of 
725 1,896 subjects who had PCR results at baseline (60.5% of them were positive) by PCR 
726 conversion at the end of treatment, and at two and five years post-treatment [47]. Being 
727 a large multi-national study, the PCR conversion rates varied geographically with 
728 Bolivia and Argentina showing the best results, though it must be noticed that such 
729 conversion did not correlate with clinical outcome [47]. BENEFIT was devised to study 
730 whether BNZ administration to patients at the chronic stage of the disease would widely 
731 have a clinical benefit for them [2122,4647]. Sadly, its conclusions, far from reassuring 
732 the role of BNZ turned out to be a setback, as they suggested not-to treat patients with 
733 advanced cardiac disease [47]. As it has been criticized elsewhere, this devastating 
734 conclusion drains from the fact that many subjects with advanced cardiac involvement 
735 were enrolled in the study [3,2122]. Despite its negative outcome due to a rather 
736 questionable study protocol design [22], the BENEFIT trial involved ample cooperation 
737 between multiple study sites opening the door to the performance of multi-national 
738 Phase 3 Chagas disease trials in South America [47]. 
739
740 7.2. Ongoing clinical trials of anti-T. cruzi drugs.
741 There are now some active and/or ongoing clinical trials. Some test alternative 
742 BNZ dosing regimens to reduce exposure, improve tolerability and maintain efficacy as 
743 described elsewhere [52], based also on the description of BNZ pharmacokinetics (PK) 
Page 53 of 99
URL: https://mc.manuscriptcentral.com/eri   Email: IERZ-peerreview@journals.tandf.co.uk





























































For Peer Review Only
23
744 in Chagas disease adult patients [80]. In others the evaluation of NFX has gained 
745 prominence under the promotion of Bayer, NFX producer. The use of fexinidazole, a 
746 nitroimidazole drug like BNZ that is being trialed for human African trypanosomiasis 
747 and leishmaniasis (respectively caused by T. cruzi closely related Kinetoplastid 
748 parasites T. brucei gambiense and T. brucei rhodensiense, and by Leishmania spp.), and 
749 of the antiarrhythmic drug amiodarone are also being clinically assessed for the first 
750 time against T. cruzi based on their anti-parasitic capacities [8081,8182]. These ongoing 
751 trials range from smaller Phase 1 to larger Phase 2 and 3 efficacy studies. There are: (1) 
752 a Phase 1 safety, tolerability and bioavailability assessment of new NFX tablets and 
753 another Phase 1 study to determine NFX PK in relation to dietary habits; (2) a Phase 2 
754 study to evaluate different BNZ regimens (MULTIBENZ); (3) another Phase 2 study to 
755 evaluate reduced and intermittent BNZ regimens, either given alone or in combination 
756 with E1224 (BENDITA); (4) two more Phase 2 studies evaluating fexinidazole to 
757 respectively determine dosing regimens and the minimal efficacious and safety dose; (5) 
758 a Phase 2-3 trial to compare safety and efficacy of NFX and BNZ (EQUITY); (6) a 
759 Phase 3 study to assess amiodarone, a commonly used antiarrhythmic with selective 
760 anti-T. cruzi properties, administered over 6 months to individuals with mild-to-
761 moderate Chagas cardiomyopathy (ATTACH); (7) a Phase 3 study of a pediatric 
762 formulation of NFX (CHICO); and (8) a very recently added Phase 3 study to evaluate a 
763 short dose of BNZ in child-bearing age women (BETTY) (Table 2). 
764 All Phase 2 or above trials in Table 2 but CHICO involve the evaluation of 
765 drugs in chronically infected adult patients, and the measurement of treatment success 
766 will rely on molecular detection of the parasite DNA. In contrast, in CHICO, designed 
767 to assess NFX performance in Chagas disease infant population, the way to measure 
768 cure is seroconversion a year after treatment because this is much easier to timely occur 
769 in children than in adults and its readout is less ambiguous than the PCR output. All 
770 these studies are currently in the recruiting stage, except FEXI NCT02498782 and 
771 CHICO which are active but not recruiting, and BETTY that is not yet recruiting 
772 (https://clinicaltrials.gov). Regarding the latter, benefits of treating T. cruzi-infected 
773 women before pregnancy have been described by several smaller studies [23–26]. 
774 Hopefully BETTY´s outcome will serve to enforce treatment administration to all child-
775 bearing age women as soon as possible.
776
777 Conclusion.
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778 Increasing the awareness on the prevalence and health impact of Chagas disease 
779 among patients, health practitioners and political health authorities may eventually 
780 translate to enhanced population-based diagnostic screening and treatment 
781 interventions. The tools needed to facilitate this activity are being tested currently in the 
782 field and incorporate more practical and point-of-care diagnostics, new drugs regimens, 
783 and the standardization of daily clinical care routines. In addition, efforts to obtain 
784 biomarkers of disease prognosis and early assessment of treatment are also being 
785 pursued and will probably yield results soon.
786 Upon failure of azoles, the majority of presently ongoing Chagas disease clinical 
787 trials either evaluate alternative regimens of current drugs or other chemical entities 
788 distinct from azoles (e.g., fexinidazole, amiodarone) with the aim to identify dosages 
789 with lower toxicity and at least equal efficacies compared to present chemotherapy with 
790 either benznidazole or nifurtimox. There is certain optimism on that a new treatment for 
791 Chagas disease can be schedul d in the next few years. Further complementing the new 
792 anti-parasitic drugs is a new therapeutic biologic, a vaccine, now advancing to the 
793 clinic. However, access to these new drugs and innovations will require enhanced 
794 policies and advocacy activities. In parallel, it will be essential to shape and disseminate 
795 pharmacovigilance protocols so that the drugs performance can be closely monitored, 
796 and patients´ and healthcare providers´ confidence on these therapies is promoted and 
797 maintained.
798 The functional deployment of counter-reference circuits fully integrated in the 
799 national health services will be required to scale up the attention to Chagas disease 
800 patients. In this regards, improved coordination between vector control authorities and 
801 sanitary authorities needs strengthening in those regions with active vector transmission 
802 of the infection. Widespread access to diagnosis and treatment will not yield the desired 
803 outcome unless chances to get re-infected are minimized or eliminated. This approach 
804 also requires maintaining blood screening and programs to stop congenital transmission. 
805 An improved maternal diagnosis and treatment protocol would in itself reduce 
806 congenital transmission.
807 Despite recently achieved advancements, Chagas disease management and 
808 control is still a huge challenge. Therefore, to succeed in this matter it will be 
809 paramount the continued involvement of key actors, including patients associations, 
810 health authorities at regional and national levels, governmental and non-governmental 
811 institutions, basic and clinical researchers, and of course financial partners.
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814 A huge drawback in the management of Chagas disease has traditionally been 
815 the lack of awareness of the disease and its impact by both health professionals and the 
816 patients themselves, as well as by governmental institutions with the power to dictate 
817 health policies. However, Chagas disease awareness is gradually increasing, so that 
818 efforts to combat this neglected tropical disease now need to shift in order to address its 
819 often insidious onset and silent clinical progression. These features currently complicate 
820 the access to timely diagnosis and treatment, which is also ballasted by the very limited 
821 resources available for research and development of improved treatment and disease 
822 prevention methodologies.
823 After so many years of neglecting Chagas disease, new efforts at R&D have the 
824 potential for high returns on investment. However, the R&D needs for Chagas disease 
825 are pervasive and span requirements for both basic and applied research, as well as new 
826 drugs, diagnostics and vaccines. With the ultimate goal of controlling the disease in 
827 endemic and non-endemic regions, the consequences of widening our understanding on 
828 Chagas disease and the pathogen that causes it will have an impact on the lives of 
829 millions of people. For instance, research on parasite-host interactions is needed to fully 
830 comprehend the pathogenic processes that lead to the life-threatening symptomatology 
831 characteristic of chronic T. cruzi infections. Furthermore, considering that in the 
832 absence of treatment ~30% of those chronically infected will develop cardiac and/or 
833 digestive tract disruptions, studies on both parasite and host genomics (and other omics) 
834 are required to determine the key factors leading to the development of pathogenesis. 
835 Deeper understanding of the parasite biology and of its interactions with the host is 
836 fundamental for the discovery of safer drugs or vaccines. Another challenge is the 
837 dearth of public policies and advocacy that so far has mostly failed to attract requisite 
838 funding. 
839 Currently the most urgent needs include an expansion in clinical studies to test 
840 an enlarged portfolio of new drugs, together with improved biomarkers to monitor 
841 disease progress. There is also urgency for inexpensive and accessible point-of-care 
842 diagnostics, especially for mass screenings as well as for the early assessment of 
843 treatment responses. Their availability will widen access to treatment because they 
844 would introduce a more accurate picture of the disease epidemiology, as well as the 
845 ability to acknowledge cure upon treatment.
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1 Title: Strategies to enhance access to diagnosis and treatment for Chagas disease 
2 patients in Latin America.
3
4 Structured abstract (maximum 200 words): 
5 Introduction: Chagas disease, caused by infection with the parasite Trypanosoma cruzi, 
6 represents a huge public health problem in the Americas, where millions of people are 
7 affected. Despite the availability of two drugs against the infection (benznidazole and 
8 nifurtimox), multiple factors impede their effective usage: 1) gaps in patient and 
9 healthcare provider awareness; 2) lack of access to diagnosis; 3) drug toxicity and 
10 absence of treatment algorithms to address adverse effects; 4) failures in drug supply 
11 and distribution; and 5) inconsistent drug efficacy against the symptomatic chronic 
12 stage. 
13 Areas covered: we review new approaches and technologies to enhance access to 
14 diagnosis and treatment as a means to reduce the disease burden. We also provide an 
15 updated picture of recently published and ongoing anti-T. cruzi drug clinical trials. 
16 Although there has been progress improving the research and development (R&D) 
17 landscape, it is unclear whether any new treatments will emerge soon. Literature search 
18 methodologies included multiple queries to public databases and the use of own-built 
19 libraries. 
20 Expert opinion: besides R&D, there is a major need for continue awareness and 
21 advocacy efforts by patient associations, local and national governments and 
22 international agencies. Overall, health system strengthening is essential to ensure vector 
23 control commitments, as well as patient access to diagnosis and treatment.
24
25 Keywords:  Chagas disease, comprehensive care, clinical trials, diagnosis, drug 
26 treatment, patients associations, pharmacovigilance, vector control.
27
28 Article highlights:
29  Chagas disease is a neglected disease caused by the parasite Trypanosoma cruzi (T. 
30 cruzi). It affects millions of people in the Americas where it has a devastating health 
31 and socioeconomic impact. The disease affects most those with lower resources, 
32 binding them to poverty and leaving them aside. It was traditionally considered a 
33 stigma, hidden by society and ignored by governments. Thankfully to medical 
34 researchers, patients’ associations and several other actors who have raised 
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35 awareness and promoted education on the disease and its management, there has 
36 been a dramatic shift towards improved diagnosis, treatment and control in recent 
37 decades.
38  There are highly sensitive and specific diagnostics for both the acute and the chronic 
39 stages of the infection. However, they are not widely implemented in many areas 
40 distant from reference laboratories due to logistical issues and the lack of equipped 
41 facilities and trained personnel. Therefore, more practical methodologies and 
42 algorithms should be used to provide point-of-care diagnostics prior to gaining 
43 access to treatment.
44  Two drugs are currently available to treat the infection: benznidazole and 
45 nifurtimox. Both are highly efficacious in newborns, but access to treatment 
46 generally occurs at the chronic stage when symptomatology arises. Due to the 
47 frequent adverse side ffects associated to their long administration regimens, 
48 pharmacovigilance programs to report drugs toxicities and a better management of 
49 these in primary care establishments must be implemented to ensure tighter 
50 adherence to medication.
51  Stronger involvement of public health institutions and authorities is fundamental to 
52 progress in the disease control and its adequate management. The establishment of 
53 counter-reference circuits integrated in national health services working plans will 
54 be fundamental to catalyze and scale up the attention and care of Chagas disease 
55 patients in endemic and non-endemic settings.
56  Although great progresses in the control of vector-related transmission has been 
57 made in some regions, there are many where vector transmission is still active. 
58 Therefore, increased cooperation between vector control programs and medical 
59 (diagnostic and treatment) programs must be put on place to maximize their impact 
60 in public health.
61  The role of patients’ associations must remain active and exert pressure on other 
62 stakeholders in order to keep up Chagas disease visibility. Patients´ organizations 
63 are at the frontline to demand attention from the responsible authorities, ensure 
64 adequate medical care, and highlight the potential returns on investment from R&D.
65 In line with the shift on the disease awareness, the clinical research landscape has 
66 recently changed for the better. At present there are several clinical trials ongoing 
67 and their results are expected to generate improvements in diagnosis and treatment 
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68 algorithms and policies in the near future. They may also lead to the advancement 
69 and licensure of new drugs, diagnostics, and vaccines.
70
71 Body of the article.
72
73
74   
75
76 1. Introduction.
77 Chagas disease, or American trypansosomiasis, is caused by the protozoan 
78 parasite Trypanosoma cruzi (T. cruzi) and remains one of the most deadly and 
79 intractable neglected tropical diseases (NTDs) in the Western Hemisphere [1].  Updated 
80 information from the Global Burden of Disease Study (GBD) 2016 indicates that 7,100 
81 people die from Chagas disease annually, roughly the same number of Chagas disease-
82 related deaths that occurred a decade previously [2]. However, these numbers may 
83 represent highly conservative estimates with further findings that as many as 200,000 
84 people living with T. cruzi infection may die over the next five years [3]. The GBD 
85 2016 also finds that 7.2 million now live with Chagas disease, while 180,000 new T. 
86 cruzi infections occur annually [4].
87 Beyond its horrific disease burden and contribution to infectious disease 
88 mortality, there is a profoundly disturbing social impact dimension to Chagas disease 
89 related to its importance as a health disparity. Today, tens of thousands of people face a 
90 death sentence from their T. cruzi infection due to Chagasic cardiomyopathy, which 
91 could be prevented by timely access to diagnosis and anti-parasitic treatment with one 
92 of two nitroheterocyclic drugs – benznidazole (BNZ) and nifurtimox (NFX). Fueling a 
93 growing outrage from the global health community is the finding that approximately 
94 90% of people infected with T. cruzi infection now live in Latin America’s three 
95 wealthiest economies: Argentina, Brazil, and Mexico. In the United States of America 
96 (USA), the richest country of the continent and main destiny of those looking for a 
97 better future, there are at least 200,000 immigrants from Latin America living with 
98 Chagas disease with limited or no access to treatment [5,6]. Furthermore, in Europe 
99 there are around 120,000 immigrants from Latin America living with Chagas diseases 
100 with a disparity of situations regarding access to care and treatment [7,8].
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101 The overwhelming majority of Chagas disease sufferers are unable to gain 
102 access to diagnosis and treatment, not only because they are poor, but also because 
103 governmental leaders are either uninformed or uninterested. For example, it is 
104 noteworthy that the registration of BNZ for the treatment of pediatric Chagas disease in 
105 the USA has not been approved until very recently [9]. Documenting such assertions is 
106 not easy and seeking solutions to diagnosis and treatment access are not straightforward 
107 endeavors. In Mexico, for example, there are almost one million people living with 
108 Chagas disease, although even that number may represent a profound underestimate 
109 [10]. Yet, only 3,013 T. cruzi infection cases were registered nationally between the 
110 years 2007 and 2011, less than 1% of the actual number of people affected with the 
111 disease [11]. A similar situation has been documented for the USA [12] and also likely 
112 holds true across the Americas. We are facing a situation where less than 1% of Chagas 
113 disease patients have access to timely and appropriate diagnosis and treatment [13,14].
114 Limiting access to essential medicines also has important implications for new 
115 research and development (R&D) related to therapeutic interventions. An exciting 
116 development on this front is a new orally bioavailable nitroheteorcyclic drug, 
117 fexinidazole, which is also effective against human African trypanosomiasis [15]. 
118 Additional drugs are also under development, as well as there are Chagas disease 
119 vaccine (immunotherapeutic) candidates at pre-clinical stage [16]. In this respect, the 
120 Texas Children’s Hospital Center for Vaccine Development, a Product Development 
121 Partnership, is exploring an approach that links therapeutic vaccination to 
122 pharmacotherapy [17]. However, any R&D successes must still face a formidable 
123 gauntlet of truncated and mostly failed global access mechanisms. Similar forces are a 
124 barrier for access to new and innovative diagnostics [18].
125 Here we report on some of the major hurdles that currently block access to the 
126 diagnosis and treatment of Chagas disease. The problems include both scientific and 
127 socioeconomic obstacles. This paper aims to elucidate the challenges they pose and 
128 offer solutions.
129
130 2. The need of more practical and useful diagnostics.
131 The poor access rate to Chagas disease therapeutic treatments has its roots in the 
132 clinical nature of the disease itself and its silent progression from the mostly 
133 asymptomatic acute stage into the symptomatic chronic one [1]. Unfortunately, 
134 biomarkers of disease progression and standardized tools to determine early response-
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135 to-treatment are yet unavailable, which greatly complicates the prognosis and follow-up 
136 of patients [19].  
137 Treatment administration, as in any other disease, needs to be preceded by an 
138 adequate diagnosis. In the case of Chagas disease, when a clinical diagnosis is achieved, 
139 tissue disruptions might already be too advanced for a chemotherapeutic intervention. 
140 Therefore, parasite detection must be sought before the onset of overt symptomatology. 
141 In the acute infection stage, for instance upon congenital transmission of the parasite, 
142 parasitemia can be detected by direct microscopic observation [1]. However, this stage 
143 is short lasting and generally goes unnoticed as there are often no symptoms at all. 
144 Approximately 30% of these infected individuals will progress to evidence either 
145 Chagasic cardiac or gastrointestinal disease. Those without clinical evidence of disease 
146 are said to be at the indeterminate stage, whereas those with cardiac or gastrointestinal 
147 involvement are at the det rminate stage. The development of life-threatening heart 
148 and/or digestive tract disruptions, which can be massive and are called mega-
149 syndromes, occurs in the long lasting chronic stage [1]. 
150 In both indeterminate and determinate Chagasic patients, parasitemia is typically 
151 low and intermittent and the diagnosis of the infection is made by means of indirect 
152 serological tests, like enzyme-linked immunosorbent assays (ELISAs). This is possible 
153 because high levels of parasite-specific immunoglobulins are produced upon T. cruzi 
154 infection (Figure 1). Anti-T. cruzi type G immunoglobulins (IgGs) levels remain above 
155 detection thresholds for many years, which is advantageous for the serological diagnosis 
156 of the infection (Figure 1). However, it turns out to be an inconvenience for a serology-
157 based assessment of drug responses as it can take several years for them to revert after 
158 the administration of treatment [20]. Another issue to take into account in the diagnosis 
159 of the infection is the wide genetic variability of the parasite, which encompasses seven 
160 different genotypes grouped in Discrete Typing Units (DTUs) [21]. A role of the 
161 parasite and host genetics interplay has been suggested in relation to the sensibility to 
162 treatment of the distinct isolates, the pathological signatures of the infection, and also in 
163 the anti-T. cruzi immune response [21].  
164 Some studies indicate that treatment interventions while patients are in the 
165 indeterminate or early determinate stages are critically important in order to prevent 
166 advanced disease progression. In contrast, from the multi-centered BENEFIT trial to 
167 evaluate BNZ efficacy it was found that patients with significant cardiac involvement 
168 progressed to advanced disease or even died despite receiving specific anti-parasitic 
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169 chemotherapy [3,21]. Currently several classifications (for instance AHCC, or 
170 Kuschnir´s modified) are in place to differentiate people with early-stage (grades A-B or 
171 0-I respectively) versus late stage (grades C-D or II-III respectively) cardiac disease. 
172 Treatment  of patients with grades C-D or II-III was not encouraged previously [1], a 
173 finding that appears to hold up in light of the recent BENEFIT findings. These findings 
174 highlight the importance of identifying both indeterminate patients with Chagas disease, 
175 and possibly those with AHCC grades A-B or modified Kuschnir grades 0-I too, since 
176 they might be successfully treated with antiparasitic therapy if they were captured 
177 during  population-wide screening campaigns [3]. In this way, it would be possible to 
178 identify and treat chronically infected people before they develop the symptomatology. 
179 Women at child-bearing age and newborns should receive special attention because the 
180 treatment of mothers-to-be has been shown to largely reduce the transmission rate [23–
181 26], and the efficacy and tolerability of current drugs by infected newborns is ~100% 
182 [1]. Moreover, health economics studies evaluating Chagas disease surveillance in 
183 endemic and non-endemic settings indicate that widespread screening would be highly 
184 cost-effective [27–30]. In the two disease scenarios studied, congenital (acute infection 
185 transmitted by chronically infected mothers) and indeterminate (chronic asymptomatic 
186 stage), mass screening would save health costs even at T. cruzi prevalence rates as low 
187 as 0.9% or 0.05% respectively (in fact estimated in a non-endemic setting) [27,29].
188 Due to the very limited resources available for Chagas disease management, and 
189 echoing the answers provided by Latin American experts enquired by Picado et al. [18], 
190 efforts should focus on making widely available point-of-care (PoC) tests to diagnose 
191 congenital transmission and indeterminate chronic patients [18]. However, if we want to 
192 enable generalized Chagas disease diagnosis, there is an urgent need of more practical 
193 diagnostic reagents and kits. Availability of easy-to-use tools for the early assessment of 
194 treatment response would also be highly valuable to promote and support the 
195 administration of drugs against the infection. In this regards, there are some biomarkers 
196 under research [19], but the evaluation of anti-T. cruzi drug responses yet relies on the 
197 molecular amplification of the parasite DNA from periphery blood obtained at distinct 
198 times post-treatment. Unfortunately, its associated high costs and technical requirements 
199 restrict its use to the context of well-funded clinical trials [31].
200
201 2.1. Current Chagas disease diagnostics are impractical in many regions.
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202 Regarding acute stage diagnostics, classical parasitological methods 
203 (micromethod, hemoculture and xenodiagnoses) are microscopy-based and rely on 
204 finding motile trypomastigotes in blood, thus they provide both low sensitivity and 
205 specificity. Due to their poor performance, current algorithm to diagnose congenital 
206 transmission involves two micromethods (at birth and at 1-2 months of age), and a 
207 further confirmatory serological test once mother-derived IgGs have waned at infant´s 
208 8-12 months of age [32]. This has two major drawbacks: a very high loss-to-treatment 
209 risk during pediatric follow up, and the reduction of drug efficacies the longer the 
210 treatment is delayed [32]. Molecular amplification of T. cruzi DNA, either by 
211 conventional polymerase chain reaction (PCR) or by quantitative PCR (qPCR), has 
212 been shown to be more sensitive and specific than classical parasitological techniques 
213 [20]. Several laboratories have worked on the standardization of the techniques so that 
214 their outcomes can be comparable and implemented in clinic-based laboratories [20]. 
215 But molecular biology laboratories are expensive to mount and maintain, plus they 
216 require highly trained personnel to run them. Therefore, despite its very good 
217 performance, molecular detection is not generally used beyond regional or national 
218 reference laboratories in endemic regions.
219 In relation to the current chronic stage diagnostics, conventional serological tests 
220 (like ELISAs, indirect immune-fluorescence or indirect hemagglutination assays) use 
221 serum or plasma samples that entail venous extraction and blood segregation by 
222 centrifugation, and they require a cold chain to preserve the test reagents and the 
223 samples. Moreover, due to the parasite´s antigenic diversity, the advice from the World 
224 Health Organization (WHO) is to run two tests based on distinct antigenic sets and if 
225 their outcomes are not concurrent, to employ a third technique [14]. This algorithm is 
226 costly, and it requires equipment and resources that are usually not available in many 
227 laboratories of endemic regions. Furthermore, the turnaround of results to the patient 
228 can take several weeks, which involves a high risk of losing contact with the patient for 
229 treatment.
230
231 2.2. What solutions could be implemented?
232 Fortunately, recent technological advancements are procuring solutions to 
233 overcome the limitations mentioned above. We will outline them separately considering 
234 first those for the diagnosis of acute stage and then those for the diagnosis of chronic 
235 Chagas disease.
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236 In recent years, isothermal amplification methods that do not require expensive 
237 equipment (such as thermocyclers or gel visualization systems) and are easier to 
238 perform than PCR assays have been developed for the molecular detection of several 
239 NTDs [20]. At present, a prototype of Loop isothermal AMPlification for T. cruzi-DNA 
240 (LAMP, Eiken Co., Japan) has been tested with clinical samples and shown to have a 
241 comparable performance to qPCR with blood-EDTA samples [33]. Another LAMP test 
242 developed in house by Rivero et al. [34] has also been shown to provide a comparable 
243 performance to current congenital transmission algorithm. LAMP is based on a 
244 microbiological DNA polymerase that works at a constant temperature of 65 ºC for 45 
245 minutes with a set of 4 to 6 complex primer sequences to provide a highly sensitive and 
246 specific amplification [35]. LAMP readout is qualitative and the results can be naked 
247 eye visualized in a short time given a probe (e.g. calcein) is added to the reaction mix. If 
248 a digital fluorimeter is used (e.g. Genie III) the reading can even be semi-quantitative 
249 [33]. Notably, in Eiken´s T. cruzi-LAMP prototype, reagents are provided dried out in 
250 the lids of the reaction tubes which allow a ready-to-use format and a much desirable 
251 room temperature storage [33]. More recently, a Recombinase Polymerase Assay 
252 (RPA), which even requires a lower amplification temperature and shorter amplification 
253 time (40 ºC for 30 min) than LAMP, has been tested with samples from naturally T. 
254 cruzi-infected dogs [36]. This RPA has been coupled to a lateral flow strip for results 
255 reading and it was shown to provide excellent agreement with qPCR results [36]. There 
256 are RPAs for the detection of other NTDs [37,38], so it could also be very useful for 
257 Chagas disease molecular diagnosis.
258 For the serological detection of T. cruzi-specific IgGs, rapid diagnostic tests 
259 (RDTs) have been commercially developed during the last two decades [39,40]. RDTs 
260 have clear advantages over conventional serology, as they can be stored at room 
261 temperature, use a very small volume (5-25 µl) of finger pricked whole blood, have an 
262 easy-to-run and read cassette format, and provide a fast turnaround of results (less than 
263 45 minutes) [40]. Several studies now support their implementation as they have been 
264 extensively validated against conventional tests [41–43]. For instance, a RDT is 
265 currently used for primary screening of chronic Chagas disease in Bolivia [41]. 
266 Nonetheless, following the WHO guidelines of two-tests concordance, confirmation of 
267 that RDT primary result must yet be made with a conventional serological test [14].  
268 Such recommendations reduce the advantages of RDTs.
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269 With the aim to fully exploit RDTs advantages and to determine whether they 
270 can substitute conventional tests, combinatory use of two RDTs has been proposed [41]. 
271 So far, in a proof-of-concept study performed in the city of Sucre (Bolivia), perfect 
272 agreement between the two RDTs used was observed, and their sensitivity and 
273 specificity in comparison with three conventional tests was 100% and 99.3%, 
274 respectively [41]. However, despite a promising performance in Bolivia [41,43], RDTs 
275 have not worked so well when they have been used in other geographical regions [44]. 
276 This might be related to the high prevalence of the disease in Bolivia, which may allow 
277 an easier detection, or to the fact that the parasite strains used to produce the RDTs 
278 antigens are those circulating in Bolivia. In any case, until more results from different 
279 epidemiological areas are available, preliminary geographical testing of the RDTs 
280 performance has been proposed before using them in a particular region [44]. In view of 
281 the advantages they bring v rsus conventional tests, RDTs implementation for Chagas 
282 disease surveillance should be valuated at larger scales. 
283
284 3. Treatment of Chagas disease, and issues related to it.
285 3.1. Drug regimens.
286 Evidence about the benefits of Chagas disease treatment, together with a 
287 growing understanding of the pathogenesis of the disease, led to the paradigm that all T. 
288 cruzi-seropositive patients should receive treatment with anti-T. cruzi drugs [45]. The 
289 recently published results of the SaMi-Trop cohort study further reaffirm this statement 
290 as they demonstrate a beneficial effect of BNZ in reducing the cardiac clinical 
291 progression of chronic Chagas disease patients [46]. Therefore, anti-trypanosomatid 
292 treatment should be provided to all T. cruzi-infected people who do not present with  
293 advanced cardiac complications (Kuschnir grades III-IV), as by then clinical 
294 manifestations might not be improved [47]. Nonetheless, access to treatment confronts 
295 important limitations. BNZ and NFX, the only drugs available for T. cruzi infection, 
296 exhibit reduced efficacy during the chronic stage of the disease, and require a long 
297 period of administration which causes frequent unwanted drug-related adverse reactions 
298 (ADRs) [48–50]. Furthermore, variable drug susceptibility has been already described 
299 among distinct T. cruzi strains [51]. In this context, there is an urgent need for more 
300 efficacious and safer drugs or drugs´ regimens, in particular for the treatment of the 
301 chronic stage of the infection.
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302 One alternative is the reduction of the BNZ dose and/or schedule in order to 
303 improve safety and adherence to treatment; an approach that is supported by clinical and 
304 experimental data. In a pilot study Álvarez et al. [52] assessed a new scheme of BNZ 
305 administration in a small cohort of chronic Chagas disease patients treated with 
306 intermittent doses of BNZ at 5 mg/kg/day every 5 days for a total of 60 days. The study 
307 showed a satisfactory safety profile, with low rates of treatment suspension and 
308 treatment failure [52]. Furthermore, an experimental study using a mouse model of 
309 chronic T. cruzi infection demonstrated the effectiveness of an intermittent scheme of 
310 BNZ administered every 5 days for 40 days [53]. These findings support the 
311 intermittent administration of BNZ as a new dosage schedule, but further research to 
312 confirm its efficacy by long-term assessment of larger cohorts is needed. Another 
313 therapeutic option under investigation is the co-administration of an immunotherapeutic 
314 (vaccine) treatment and BNZ. In this regards, enhancement of a T. cruzi-specific 
315 immune response has been shown to contribute to support the efficacy of reduced BNZ 
316 dosages in a mouse model of acute T. cruzi infection [17].
317
318 3.2. Drug availability.
319 Drug access is still a huge problem in some endemic areas [13]. BNZ, generally 
320 the first line therapy for Chagas disease, is part of the WHO List of Essential Medicines 
321 [54]. It was produced during more than 40 years by Roche (Basilea, Switzerland), 
322 which transferred its production rights to Laboratório Farmacêutico de Pernambuco 
323 (LAFEPE), a Brazilian public enterprise, at the end of the twentieth century. Sadly, 
324 BNZ production and distribution by LAFEPE failed to meet expectations in terms of 
325 meeting supply and demand requirements and in 2011 an important shortage of the drug 
326 occurred. It lasted 1.5 years and left thousands of patients without treatment worldwide 
327 [13,55]. This fact led to the development of a Private-Public Partnership in Argentina 
328 involving Maprimed (for the synthesis of the drug) and ELEA (for its development and 
329 production), to promote equitable availability of BNZ [56]. Since 2012, this Argentinian 
330 Partnership has worked to guarantee the availability of the drug, distributing BNZ to the 
331 countries in the region [56]. NFX, which is mostly used as the second line treatment 
332 option, is produced and donated by the pharmaceutical company Bayer, and distributed 
333 through the Pan-American Health Organization (PAHO) Strategic Fund [57]. Recently, 
334 a NFX produced by Gador has also been registered in Argentina. Definitely, a regular, 
335 safe and accessible production of these two anti-parasitic drugs is necessary to 
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336 guarantee the treatment to diagnosed patients, and the access to drugs has to be ensured 
337 in adequate quantity, quality, location and timing.
338
339 3.3. Pharmacovigilance.
340 A major limitation of current Chagas disease treatments is the onset of Adverse 
341 Drug Reactions (ADRs), which may lead to poor medication adherence, and cause 
342 thereby therapeutic failure or ineffective treatment [48-50]. ADRs are defined as "an 
343 appreciably harmful or unpleasant reaction, resulting from an intervention related to the 
344 use of a medicinal product, which predicts hazard from future administration and 
345 warrants prevention or specific treatment, or alteration of the dosage regimen, or 
346 withdrawal of the product” [58]. The most commonly observed ADRs related to BNZ 
347 are headache, dermatological manifestations and gastrointestinal symptoms [49,50]. 
348 Concerning NFX, digestive symptoms are the most frequent [48]. Nevertheless, with an 
349 adequate clinical management most of the patients are able to finish treatment in the 
350 advent of ADRs [49]. Close medical follow-up, adequate monitoring of ADRs and 
351 implementation of robust pharmacovigilance systems are essential factors to avoid 
352 patient abandonment and achieve therap utic success.
353 Although pharmacovigilance is crucial, it is still a neglected area. Latin-
354 American countries are making important efforts to report ADRs, but these activities are 
355 recent and need reinforcement [59,60]. Results of an unpublished study conducted by 
356 Cortes-Serra et al. in Bolivia during 2016 indicate that 35.4% of the total patients 
357 treated for Chagas disease in fourteen healthcare centers of the department of 
358 Cochabamba suffered ADRs related to it. From all ADRs classified as moderate or 
359 severe (25% of the total ADRs registered), only about half of them (51.43%) were 
360 reported to the Bolivian Pharmacovigilance system [61]. This data illustrates the 
361 urgency of implementing policies to promote training in pharmacovigilance to all 
362 healthcare professionals, as well as strictly recommend the follow-up on drug 
363 monitoring and ADR reporting. Altogether, these features are fundamental to achieve 
364 strong and consolidated ADR reporting systems, which will improve patient safety, 
365 drug efficacy and adherence to treatment. 
366
367 4. Patients´ comprehensive care: reference and counter-reference circuits.
368 With less than 1% people treated [13,14], and an economic burden of $7.19 
369 billion per year and $188.8 billion per lifetime [62], Chagas disease remains neglected 
Page 77 of 99
URL: https://mc.manuscriptcentral.com/eri   Email: IERZ-peerreview@journals.tandf.co.uk





























































For Peer Review Only
12
370 despite the efforts performed by several institutions focused on development and 
371 research [13]. Migratory flows have changed the epidemiology of the disease that is 
372 now emerging in some non-endemic countries [7]. During the last decades, 
373 collaboration and knowledge transfer between institutions from endemic (CEADES, 
374 Bolivia) and non-endemic countries (ISGlobal, Spain) has been strategic to build 
375 attention models for the Chagas disease patient. Such models could be scaled-up by 
376 national health systems in endemic and non-endemic countries in order to expand 
377 Chagas disease healthcare to people living in areas with limited access to health (e.g. 
378 rural areas in endemic countries) or to vulnerable populations (e.g. migrants in endemic 
379 and non-endemic countries).
380
381 4.1. The Platform for integral care of Chagas disease patients.
382 The work made by this Platform in recent years have produced a quantitative 
383 and qualitative improvement in the healthcare provided to Chagas disease patients in 
384 Bolivia, but this improvement certainly needs to be strengthened. The experience gained 
385 with the Platform in the country has shown that the implementation of specialized 
386 centers to manage people at risk of having Chagas disease is highly effective, both 
387 based on the percentage (and number) of people diagnosed with the infection, and 
388 amongst them, those who received and completed treatment [63]. This vertical strategy 
389 has been essential to design the attention model for patients with Chagas, making the 
390 medical assistance to these people look like a normalized and necessary action [63]. 
391 Nevertheless, the sustainability of such model ultimately depends on continuously 
392 securing external funds, which greatly complicates its expansion to larger geographical 
393 levels, like national coverage by the national health system (Figure 2).
394
395 4.2. Vertical-to-horizontal healthcare model transition.
396 In order to have a higher impact in terms of diagnosis and treatment coverage, as 
397 well as to ensure the sustainability for the model of care of Chagas disease patients 
398 already installed, it is mandatory to search for a comprehensive horizontal strategy 
399 together with local higher level entities of the public health system. In fact, based on 
400 WHO recommendations, the strategy to include the Chagas disease attention roadmap 
401 as part of the regular activities of all healthcare levels seems to be the most appropriate 
402 approach [64].
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403 Simplifying the vertical Chagas disease model of healthcare to more realistic 
404 protocols established together with the national health institutions has allowed the 
405 improvement of healthcare access for people at risk of having the disease living in 
406 remote areas of an endemic country [63]. Researchers at ISGlobal (authors of this 
407 review) have yet unpublished data which demonstrate that the health coverage, in terms 
408 of patients diagnosed and treated in the selected area in which the project has expanded 
409 its activity, was five times higher in the three years following the horizontal 
410 comprehensive care model than the number of people covered in the five previous years 
411 with the vertical strategy (Pinazo et al., unpublished).
412 So far, the outcome of the vertical-to-horizontal healthcare model transition 
413 highlight that it could be worthy to replicate and/or adapt it to other regions or 
414 countries. The first step would be to coordinate with local health authorities at different 
415 levels in order to design an appropriate strategy. For the implementation of a healthcare 
416 model, the identification of interested health workers is a key issue. Even if it is 
417 simplified, a strategy to offer a comprehensive care for people at risk of suffering from 
418 Chagas disease should include: (a) specific training of health workers on the disease 
419 management; and (b) a strategy to incr ase the demand of the civil society, based on 
420 promotional and educational community activities. In this regard, the establishment of 
421 referral and counter-referral circuits tailored to each epidemiological and logistic 
422 situation is highly relevant, even in nearby areas.
423
424 4.3. Requirements for the expansion of the Chagas disease healthcare model.
425 Referral and counter-referral circuits, in terms of patients and samples for 
426 diagnosis or any other test, should include different healthcare levels to cover different 
427 levels of complexity in terms of care. The specialized centers in which the model of care 
428 has been rehearsed in Bolivia are key towards organizing these circuits, as well as to act 
429 as reference centers for complicated cases and to accompany the doubts and the 
430 continuing education of health professionals from primary care centers. This is 
431 particularly important in health systems where there is often a fast renewal of healthcare 
432 personnel. Another crucial point to make sustainable a comprehensive horizontal 
433 strategy against Chagas disease is to promote an inter-sectorial collaboration with vector 
434 control authorities (promoters of house refurbishment, disinfestation programs,...) and 
435 the educational system itself. Vector control interventions are fundamental to halt 
436 vector-dependent transmission and enable an enhanced drug control of the cases. 
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437 Whereas educational activities to widen the population knowledge and perception of the 
438 disease, its impact, and treatment possibilities are crucial, because producing changes in 
439 beliefs, attitudes, and behaviors on both medical staff and patients still stands as one of 
440 the major challenges that must be faced when dealing with Chagas disease. All these 
441 measures have a role to play in order to consolidate the successful management of the 
442 disease.
443 On the other hand, lessons learned from the primary healthcare network have 
444 shown that it is mandatory to ensure the supervision of the circuits and surveillance the 
445 quality of the process, tasks that should be carried out by the national health system 
446 responsible personnel in duty. Political engagement at this point is mandatory to 
447 contribute to a better control of the disease as a Public Health problem. In this context, 
448 it is important to respect the capability of local health institutions, agreeing with them 
449 timelines and a progressive increase of the number of people diagnosed and treated, in 
450 order to answer adequately to people’s demands. It must be noted that external factors 
451 like the poor availability of drugs for Chagas disease treatment have a sourly negative 
452 impact on any planning.
453
454 5. Patients treatment in relationship with vector control.
455 Access to diagnosis and treatment of Chagas disease in areas with active vector 
456 transmission requires a multidisciplinary approach. It involves the participation of 
457 players from several areas of expertise and different government sectors, from vector 
458 control authorities to health service providers, including primary healthcare [65].
459 Following the advice from the PAHO, intergovernmental regional initiatives 
460 were created at the end of the twentieth century and beginning of the twenty first 
461 century to establish supranational levels of action to bolster and monitor the 
462 implementation of activities to prevent, control, diagnose and treat Chagas disease in 
463 Latin America. These initiatives were started by Southern Cone countries in 1991, and 
464 then followed by Andean countries and Central American countries in 1997 and 
465 Amazonian countries in 2004 [66,67]. Despite these efforts, it is evident that in the 
466 region there was, and still is, a breach between the programs for vector control and the 
467 areas that are responsible for providing universal health care (including diagnosis and 
468 etiological treatment) [68].
469 It is important to consider that although policies related to the primary 
470 prevention of Chagas disease are defined at the national level, primary healthcare 
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471 attention for the patient is the responsibility of the provincial/departmental or 
472 municipal/local entities [69]. Often times, these final effectors of national policies have 
473 little or no relation/communication with the national entity and are sometimes even 
474 unaware of the policies themselves. For example, suggestion of treatment of the 
475 infection by T. cruzi for postpartum women and their newborns, and the mandatory 
476 treatment for women of childbearing age and children under the age of one with Chagas 
477 disease that are in the national or supranational norms [32], make no specific mention of 
478 which protocols need to be applied with respect to vector surveillance in the houses of 
479 those patients living in endemic areas with active vector transmission. However, recent 
480 public health interventions have shown that activities related to access to diagnosis or 
481 treatment of the disease are usually implemented and promoted by those responsible for 
482 vector control programs [70]. Thus, without consideration of the need of appropriate 
483 structures and circuits (i.e. access to an adequate laboratory for diagnosis or presence of 
484 anti-trypanosomal drugs), which are not usually present in rural areas, one of the main 
485 actions needed is to establish and/or strengthen the link between vector control 
486 programs and the health system providers [70]. Thereafter, following a stepwise 
487 approach, another action to accomplish would be to provide technical recommendations 
488 to establish criteria for categorizing the risk of vector transmission status in an endemic 
489 area. With that information available, it could be possible to explicitly detail under 
490 which conditions Chagas disease diagnosis and treatment has to be made mandatory in 
491 the area for the entire population, or segments of it (i.e. women at childbearing age, 
492 newborns). Finally, a most desired third action would definitely be to integrate the 
493 procedures for disease diagnosis and treatment within the health system as a transversal 
494 program.
495 Nowadays there are already a few experiences that have been able to coordinate 
496 vector control actions together with diagnosis and treatment in a successful manner [71, 
497 72]. These could serve as proof-of-concept strategies for integral interventions to build 
498 on, improve and replicate. As an example, the experience of Fundación Mundo Sano, 
499 with direct and uninterrupted action in the field since 2002, is worth mentioning. Its 
500 integral program includes vector control and sanitary improvement of rural houses in 
501 the Department of General Taboada (Santiago del Estero, Argentina). In 2015, after 13 
502 years of vector surveillance and control, Mundo Sano was able to install two doctors’ 
503 offices dedicated to the diagnosis and treatment of Chagas disease together with local 
504 institutions, one in Añatuya City and another one in Colonia Dora. Since then, they have 
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505 been struggling with the problems of having a mono-disease health service in a 
506 community that did not demand treatment. Despite the difficulties, after almost three 
507 years of implementation, the amount of people diagnosed and treated begun to increase. 
508 The work from these two Chagas disease specific offices was integrated to the local 
509 hospital of Añatuya in 2018, thus reaching a higher amount of T. cruzi-infected 
510 individuals derived from obstetrics, gynecology and cardiology services in addition to 
511 those attending the offices from spontaneous demand. In the same line, the Platform for 
512 the Integral Care of Chagas disease Patients was settled in Bolivia in 2009. Initially in 
513 the province of Cochabamba in the center of the country, the Platform now works also 
514 in municipalities f the provinces of Chuquisaca and Tarija [63]. Each experience, 
515 proposal or pilot study must be evaluated objectively in order to improve and multiply 
516 its impact, avoiding a future with a new inequality: one were those affected by the 
517 disease will have access to health depending on whether they live in an endemic or non-
518 endemic area.
519
520 6. The role of patients’ associations.
521 Similarly to what happens with other NTDs programs to promote scaling up of 
522 healthcare interventions, strategies towards the control of Chagas disease often confront 
523 with structural weaknesses of the health systems in which they aim to be integrated [73–
524 75]. Therefore, more effective strategies to strengthen those health systems are required 
525 to ensure a sustainable integration of the required health innovations within them. 
526 Importantly, these strategies need to incorporate the patients´ perspective in order to 
527 overcome key access barriers [13,14,75]. Barriers that nowadays still hinder the access 
528 to diagnosis and treatment, barriers impeding a better health care.
529 In recent years, several associations of Chagas disease patients have emerged 
530 and joined in a Federation of Associations whose purposes are: (i) to increase the 
531 visibility of the disease at all levels as well as of its overwhelming impact in the 
532 patients´ health status; and (ii) to promote a more active role of the people affected by 
533 the disease in the decision-making processes. But these associations face many 
534 difficulties (dispersion of objectives, multiplicity of voices with different requirements, 
535 little real mobilization in many countries, and lack of resources) to achieve their 
536 objective of having an effective role in the health policies makings of their countries.
537 The WHO global strategy on integral health services centered on people could 
538 be a way through which these associations can play an important practical role [77]. In 
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539 fact one of the goals of such program is to empower individuals, families and 
540 communities by including in it some well-known activities led by patients such as 
541 community education, groups of patients for mutual support, expert patients to engage 
542 and help others, etc. [77]. In addition, this WHO program goes beyond a single disease 
543 and has the virtue of encompassing other actors with decisive roles in health systems 
544 performance, like governmental policy-makers, municipalities, donors, and providers. 
545 Overall, the strategy is thus envisaged to allow the community and patients to 
546 actively participate in the decision-making process, together with other involved actors, 
547 in issues regarding their health. By doing so, they also play a role on the way the health 
548 system is organized, for instance ensuring that community and primary healthcare are 
549 prioritized. Therefore, patients associations should look after the implementation and 
550 compliance with this WHO strategy as it underlies the activities they are already taking 
551 on.
552
553 7. The R&D Agenda: clinical trials for new drugs or new strategies of treatment 
554 with current drugs.
555 7.1. Results from recently completed trials.
556 Upon the questioned efficacy of currently available therapies (BNZ and NFX) 
557 against the chronic symptomatic stage of the disease, clinical testing of new drugs 
558 and/or of new regimens of BNZ and NFX is being pursued. Nonetheless, some major 
559 obstacles are in the way to getting more adequate treatments, including the poor 
560 understanding of the infection pathophysiology leading to the disease clinical 
561 progression, and the lack of biomarkers to determine prognosis and cure (see review by 
562 Pinazo et al., [19]). Particularly the latter hinders the follow-up of treated patients both 
563 in the daily clinic and in clinical trials. At present, an absence of molecular 
564 amplification of T. cruzi DNA from periphery blood is used as surrogate of “treatment 
565 success”. But this approach is far from optimal, especially at the chronic stage of the 
566 disease when the parasitemia is low and intermittent. A negative result obtained at a 
567 determined time point does not exclude the possibility that a positive one will be 
568 obtained in the next visit. A false-negative PCR, i.e., a negative PCR result (“treatment 
569 success” event) in the patient follow up is then less informative than a positive 
570 determination, as this one will indeed define a case of treatment failure.   
571 Despite this limitation, several clinical trials have been completed in the last 
572 years, and there are several more currently ongoing. This advance represents a major 
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573 shift in the research landscape of this historically forgotten NTD. The vast majority of 
574 the performed trials have been Phase 2 randomized, multi-centric, double-blinded, 
575 efficacy and safety studies to evaluate oral dosage schemes for the treatment of adult 
576 patients at indeterminate (asymptomatic) chronic stage (see Table 1). Amongst them, 
577 CHAGASAZOL [78], STOP CHAGAS [79] and E1224 [31] have evaluated for the first 
578 time two triazole anti-fungal drugs (posaconazole (POS), and the ravuconazole 
579 precursor E1224) for their anti-T. cruzi properties. In addition, the BENEFIT trial that 
580 evaluated the use of BNZ for chronic stage treatment must also be highlighted as it has 
581 been the largest Phase 3 Chagas disease trial performed so far [47].
582 CHAGASAZOL and E1224 trials entailed a direct comparison of POS and 
583 E1224 monotherapy at a high and a low dose to a BNZ standard dosage group (5 
584 mg/kg/day orally divided in two daily doses for 60 days) [31,78]. In addition to 
585 monotherapy branches, STOP CHAGAS trial also included a study group that received 
586 POS and BNZ as combined therapy [79]. In the latter, treatment success was defined as 
587 a negative PCR value at the day 180 follow-up visit [79], whereas parasitological cure 
588 in CHAGASAZOL was determined by a negative PCR result at 12 months follow-up 
589 [78]. The most stringent success criteria was that of E1224 trial, which involved serial 
590 negative PCR results (3 negative PCR results from 3 samples collected over 7 days) at 
591 65 days after end of treatment and a further negative PCR outcome at 12 months follow-
592 up [31]. 
593 Although both POS and E1224 drugs showed good safety and efficacy profiles 
594 at end of treatment in the three studies, the suppressive effect on parasite clearance after 
595 12 months was much reduced in comparison to BNZ, which showed early and sustained 
596 efficacy until 12 months of follow-up (Table 1). Thus, neither POS nor E1224 were as 
597 good as BNZ and could not substitute it as monotherapies.
598 In the BENEFIT trial, the treatment response was evaluated in a sub-group of 
599 1,896 subjects who had PCR results at baseline (60.5% of them were positive) by PCR 
600 conversion at the end of treatment, and at two and five years post-treatment [47]. Being 
601 a large multi-national study, the PCR conversion rates varied geographically with 
602 Bolivia and Argentina showing the best results, though it must be noticed that such 
603 conversion did not correlate with clinical outcome [47]. BENEFIT was devised to study 
604 whether BNZ administration to patients at the chronic stage of the disease would widely 
605 have a clinical benefit for them [22,47]. Sadly, its conclusions, far from reassuring the 
606 role of BNZ turned out to be a setback, as they suggested not-to treat patients with 
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607 advanced cardiac disease [47]. As it has been criticized elsewhere, this devastating 
608 conclusion drains from the fact that many subjects with advanced cardiac involvement 
609 were enrolled in the study [3,22]. Despite its negative outcome due to a rather 
610 questionable study protocol design [22], the BENEFIT trial involved ample cooperation 
611 between multiple study sites opening the door to the performance of multi-national 
612 Phase 3 Chagas disease trials in South America [47]. 
613
614 7.2. Ongoing clinical trials of anti-T. cruzi drugs.
615 There are now some active and/or ongoing clinical trials. Some test alternative 
616 BNZ dosing regimens to reduce exposure, improve tolerability and maintain efficacy as 
617 described elsewhere [52], based also on the description of BNZ pharmacokinetics (PK) 
618 in Chagas disease adult patients [80]. In others the evaluation of NFX has gained 
619 prominence under the promotion of Bayer, NFX producer. The use of fexinidazole, a 
620 nitroimidazole drug like BNZ that is being trialed for human African trypanosomiasis 
621 and leishmaniasis (respectively caused by T. cruzi closely related Kinetoplastid 
622 parasites T. brucei gambiense and T. brucei rhodensiense, and by Leishmania spp.), and 
623 the antiarrhythmic drug amiodarone are also being clinically assessed for the first time 
624 against T. cruzi based on their anti-parasitic capacities [81,82]. These ongoing trials 
625 range from smaller Phase 1 to larger Phase 2 and 3 efficacy studies. There are: (1) a 
626 Phase 1 safety, tolerability and bioavailability assessment of new NFX tablets and 
627 another Phase 1 study to determine NFX PK in relation to dietary habits; (2) a Phase 2 
628 study to evaluate different BNZ regimens (MULTIBENZ); (3) another Phase 2 study to 
629 evaluate reduced and intermittent BNZ regimens, either given alone or in combination 
630 with E1224 (BENDITA); (4) two more Phase 2 studies evaluating fexinidazole to 
631 respectively determine dosing regimens and the minimal efficacious and safety dose; (5) 
632 a Phase 2-3 trial to compare safety and efficacy of NFX and BNZ (EQUITY); (6) a 
633 Phase 3 study to assess amiodarone, a commonly used antiarrhythmic with selective 
634 anti-T. cruzi properties, administered over 6 months to individuals with mild-to-
635 moderate Chagas cardiomyopathy (ATTACH); (7) a Phase 3 study of a pediatric 
636 formulation of NFX (CHICO); and (8) a very recently added Phase 3 study to evaluate a 
637 short dose of BNZ in child-bearing age women (BETTY) (Table 2). 
638 All Phase 2 or above trials in Table 2 but CHICO involve the evaluation of 
639 drugs in chronically infected adult patients, and the measurement of treatment success 
640 will rely on molecular detection of the parasite DNA. In contrast, in CHICO, designed 
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641 to assess NFX performance in Chagas disease infant population, the way to measure 
642 cure is seroconversion a year after treatment because this is much easier to timely occur 
643 in children than in adults and its readout is less ambiguous than the PCR output. All 
644 these studies are currently in the recruiting stage, except FEXI NCT02498782 and 
645 CHICO which are active but not recruiting, and BETTY that is not yet recruiting 
646 (https://clinicaltrials.gov). Regarding the latter, benefits of treating T. cruzi-infected 
647 women before pregnancy have been described by several smaller studies [23–26]. 
648 Hopefully BETTY´s outcome will serve to enforce treatment administration to all child-
649 bearing age women as soon as possible.
650
651 Conclusion.
652 Increasing the awareness on the prevalence and health impact of Chagas disease 
653 among patients, health practitioners and political health authorities may eventually 
654 translate to enhanced population-based diagnostic screening and treatment 
655 interventions. The tools needed to facilitate this activity are being tested currently in the 
656 field and incorporate more practical and point-of-care diagnostics, new drugs regimens, 
657 and the standardization of daily clinical care routines. In addition, efforts to obtain 
658 biomarkers of disease prognosis and early assessment of treatment are also being 
659 pursued and will probably yield results soon.
660 Upon failure of azoles, the majority of presently ongoing Chagas disease clinical 
661 trials either evaluate alternative regimens of current drugs or other chemical entities 
662 distinct from azoles (e.g., fexinidazole, amiodarone) with the aim to identify dosages 
663 with lower toxicity and at least equal efficacies compared to present chemotherapy with 
664 either benznidazole or nifurtimox. There is certain optimism on that a new treatment for 
665 Chagas disease can be scheduled in the next few years. Further complementing the new 
666 anti-parasitic drugs is a new therapeutic biologic, a vaccine, now advancing to the 
667 clinic. However, access to these new drugs and innovations will require enhanced 
668 policies and advocacy activities. In parallel, it will be essential to shape and disseminate 
669 pharmacovigilance protocols so that the drugs performance can be closely monitored, 
670 and patients´ and healthcare providers´ confidence on these therapies is promoted and 
671 maintained.
672 The functional deployment of counter-reference circuits fully integrated in the 
673 national health services will be required to scale up the attention to Chagas disease 
674 patients. In this regards, improved coordination between vector control authorities and 
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675 sanitary authorities needs strengthening in those regions with active vector transmission 
676 of the infection. Widespread access to diagnosis and treatment will not yield the desired 
677 outcome unless chances to get re-infected are minimized or eliminated. This approach 
678 also requires maintaining blood screening and programs to stop congenital transmission. 
679 An improved maternal diagnosis and treatment protocol would in itself reduce 
680 congenital transmission.
681 Despite recently achieved advancements, Chagas disease management and 
682 control is still a huge challenge. Therefore, to succeed in this matter it will be 
683 paramount the continued involvement of key actors, including patients associations, 
684 health authorities at regional and national levels, governmental and non-governmental 
685 institutions, basic and clinical researchers, and of course financial partners.
686
687 Expert Opinion.
688 A huge drawback in th  management of Chagas disease has traditionally been 
689 the lack of awareness of the disease and its impact by both health professionals and the 
690 patients themselves, as well as by governmental institutions with the power to dictate 
691 health policies. However, Chagas disease awareness is gradually increasing, so that 
692 efforts to combat this neglected tropical disease now need to shift in order to address its 
693 often insidious onset and silent clinical progression. These features currently complicate 
694 the access to timely diagnosis and treatment, which is also ballasted by the very limited 
695 resources available for research and development of improved treatment and disease 
696 prevention methodologies.
697 After so many years of neglecting Chagas disease, new efforts at R&D have the 
698 potential for high returns on investment. However, the R&D needs for Chagas disease 
699 are pervasive and span requirements for both basic and applied research, as well as new 
700 drugs, diagnostics and vaccines. With the ultimate goal of controlling the disease in 
701 endemic and non-endemic regions, the consequences of widening our understanding on 
702 Chagas disease and the pathogen that causes it will have an impact on the lives of 
703 millions of people. For instance, research on parasite-host interactions is needed to fully 
704 comprehend the pathogenic processes that lead to the life-threatening symptomatology 
705 characteristic of chronic T. cruzi infections. Furthermore, considering that in the 
706 absence of treatment ~30% of those chronically infected will develop cardiac and/or 
707 digestive tract disruptions, studies on both parasite and host genomics (and other omics) 
708 are required to determine the key factors leading to the development of pathogenesis. 
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709 Deeper understanding of the parasite biology and of its interactions with the host is 
710 fundamental for the discovery of safer drugs or vaccines. Another challenge is the 
711 dearth of public policies and advocacy that so far has mostly failed to attract requisite 
712 funding. 
713 Currently the most urgent needs include an expansion in clinical studies to test 
714 an enlarged portfolio of new drugs, together with improved biomarkers to monitor 
715 disease progress. There is also urgency for inexpensive and accessible point-of-care 
716 diagnostics, especially for mass screenings as well as for the early assessment of 
717 treatment responses. Their availability will widen access to treatment because they 
718 would introduce a more accurate picture of the disease epidemiology, as well as the 
719 ability to acknowledge cure upon treatment.
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CHAGASAZOL 01162967 POS 78 >80% (POS)
38.4% (BNZ)
[77]






E1224 01489228 E1224 231 ≥81% (E1224)
18% (BNZ)
[30]
BENEFIT 00123916 BNZ 2854 
(1896)3
44.6% (BNZ)4 [46]
1Clinical trial identification number (check it out at https://clinicaltrials.gov).
2Study outcome shown as treatment failure measured by PCR; STOP CHAGAS entry 
also includes the failure rate in the POS+BNZ group.
3,4Number in parenthesis stands for the number of patients with a PCR result at baseline 
of which 60.5% were positive. The outcome shown indicates the % of initially PCR 
positive patients who were reported PCR positive again at two years. 
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Study type No. Patients 
(estimated)
Promoter
- 03350295 NFX Phase 1 48 Bayer
- 03334838 NFX Phase 1 36 Bayer
MULTIBENZ 03191162 BNZ Phase 2 240 Hospital Vall 
d´Hebron 
(Spain)
BENDITA 03378661 BNZ and 
E1224





FEXI Phase 2 140
45
DNDi
EQUITY 02369978 NFX and 
BNZ




ATTACH 03193749 AMD Phase 3 200 Fundación 
Cardioinfantil 




CHICO 02625974 NFX Phase 3 330 Bayer
BETTY 03672487 BNZ Phase 3 600 Tulane 
University 
(USA)
1Clinical trial identification number (check it out at https://clinicaltrials.gov).
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1Clinical trial identification number (check it out at https://clinicaltrials.gov).
2Study outcome shown as treatment failure measured by PCR; STOP CHAGAS entry 
also includes the failure rate in the POS+BNZ group.
3,4Number in parenthesis stands for the number of patients with a PCR result at baseline 
of which 60.5% were positive. The outcome shown indicates the % of initially PCR 
positive patients who were reported PCR positive again at two years. 
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